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The functional recovery of lacerated skeletal muscles can be slow and incomplete. A 
damaged intra-muscular nerve has previously been shown to influence recovery. The study 
investigates gene and protein expression profiles of neurotrophic factors, atrophic factors 
and fibrosis factors during the early (2-weeks) and late (12-weeks) phase of repair using the 
medial gastrocnemius of adult male Sprague-Dawley rats. It is hypothesized that specific 
endogenous anti-fibrosis, anti-atrophic and anti-re-innervation targets can improve muscle 
and intra-muscular nerve axonal regeneration in the early phase post-laceration. The gene 
and protein expression levels of NT4, GDNF, CNTF, IGF1, HGF, Galectin-1 and EGF in 
lacerated muscle models involving different intramuscular nerve injuries were studied. In the 
intramuscular nerve preserved intact (PN), there is a greater reduction in collagen (3.25-
fold), vimentin (0.21-fold) and aggrecan (0.24-fold) expression than intramuscular nerve cut 
group (DN) at 12-weeks post-laceration. This correlates positively with a marked increase in 
AMPK-1a (2.96-fold), decorin (11.28-fold) and EGF (3.24-fold) expression at 12-weeks in 
PN. Fibrosis in DN (denervated muscle) is driven by high NT4 (24.86-fold) and TGFb2 
(0.21-fold) expression. Fibrosis then promotes chronic denervation via up-regulation of 
collagen-1 and aggrecan, which leads to more atrophy in DN. This is evident as there is a 
greater increase in atrogin-1 (3.76-fold) and MuRF-1 (3.44-fold) expression in DN than in 
PN at 12-weeks post-laceration, resulting from higher myogenin (10.81-fold) and myostatin 
(0.85-fold) expression, and lower IGF1 (0.15-fold), CNTF (1.34-fold), GDNF (17.78-fold) 
and EGF (2.44-fold) expression. DN also has abundant immature muscle fibers with small 
size and central nuclei at lacerated site, while PN had more mature, fully differentiated adult 
muscle fibers with large cross-sectional area and multiple nuclei at the periphery. The 
decrease in myogenesis in DN is mediated by high TGFb2 and myostatin expression. 
Chronic denervation in DN leads to incomplete differentiation of young myofibers into 
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mature adult muscle fibers to replace dead muscle fibers. DN suffered more permanent fiber 
type transformation, with lower fast myosin heavy chain (0.043-fold) and fast troponin-I 
(0.14-fold). This re-distribution of myosin heavy chains and troponin-I is responsible for the 
loss of muscle force and power in DN rats. Intra-muscular nerve regeneration in PN is better 
than DN as PN has the highest GAP43 expression level at 12-weeks (0.85-fold) while DN 
has the lowest GAP43 expression (0.59-fold). This great reduction in GAP43 activity in DN 
is due to aggressive fibrosis which inhibited axonal regeneration and high complement-3 
(6.61-fold) expression which destroyed the newly regenerating axons. Our results showed 
that the integrity of the intra-muscular nerve can regulate fibrosis, atrophy, intra-muscular 
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1)  INTRODUCTION 
Laceration of skeletal muscle involving the intra-muscular nerve is frequently 
encountered in trauma of the extremities. The muscle lacerations are repaired by epimysial 
suturing, followed by immobilization (Kragh et al, 2005).  Although it is possible to repair 
damaged the intra-muscular nerves in lacerated skeletal muscle following traumatic injury 
by micro-anastomosis, this is technically difficult. Also, micro-anastomosis of the intra-
muscular nerve cannot prevent the formation of fibrosis at the lesion site. These results in 
irreversible atrophy with muscle mass and function not fully returned as the muscle 
remained permanently denervated. 
The re-innervation of lacerated skeletal muscle is tightly regulated by an orchestrated 
expression of growth factors, cell adhesion molecules, extracellular matrix proteoglycans 
and axonal guidance molecules during different phases of muscle regeneration. This process 
involves re-connection of alpha motor neurons to their endplates, re-connection of gamma 
motor neurons to spindles, and re-growth of sensory axons into muscle. The latter comprise 
several types of axons such as unmyelinated nociceptive axons and large myelinated axons 
that re-innervate muscle spindles. After injury, terminal Schwann cells first cluster at 
denervated endplates to facilitate reconnection. Regenerating motor axon terminals are then 
guided to denervated endplates initially by growing along a lining of old Schwann cells from 
the proximal stump of the cut nerve.  
Another potential source of growing axons is from axonal sprouts from adjacent 
intact muscles. This may take more than 3-4 months because few regenerating axons can 
successfully cross the gap between the proximal and distal nerve stumps if the gap is more 
than 3mm even after micro-surgical repair. Hence the lacerated muscle may be innervated by 
several sprouts (polyneuronal innervations). Polyneuronal innervation is eventually pruned 
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when functional neuromuscular synapse is established.  
Not all of the regenerating axons will achieve the desired re-innervation of the limb 
skeletal muscles. Those that do reach the muscle can prevent denervation-induced atrophy 
(Borisov et al, 2001). Some axons will fail to reach their targets completely whereas others 
will grow in a misdirected fashion. This inappropriate muscle re-innervation can lead to 
random nerve sprouting in a mass of scar tissue, resulting in poor functional muscle 
recovery. The poor muscle recovery can become irreversible with muscle fibers at the lesion 
site being replaced by non-contractile collagen fibers. This then leads to simultaneous 
contraction of antagonistic muscles and mass movement, and so effective movement to the 
traumatised limb cannot be restored (Fu and Gordon, 1995).  
Several studies support the proposition that re-innervation of the peripheral nerve at 
the early repair phase can influence the recovery of the lacerated muscle post-surgery (Fu 
and Gordon, 1995; Borisov et al, 2001). For example, the range of recovery of the muscle 
mass in a lacerated muscle (Kragh et al, 2005) or in a denervated muscle (Fu and Gordon, 
1995; Borisov et al., 2001) over a period of more than 3-4 months is reported to be between 
60% and 80%. In our previous studies (Pereira et al, 2006; Pereira et al, 2010), we reported 
that the recovery of muscle mass in a lacerated rabbit muscle model with damaged intra-
muscular nerve is not more than 80% even up to a period of 7 months. Although several 
gene expression studies targeted at various muscle injury models have examined various 
genes involved in improved muscle repair (Zhou et al, 2006), none have looked specifically 
at the gene expression profiles in lacerated skeletal muscles with damaged intra-muscular 
nerves.   
Thus, the early regenerative response at the lesion site of a lacerated muscle where 
both the muscle and nerves are damaged has not been completely characterized.  It is still 
unknown if the damaged intra-muscular nerve can influence the acute inflammatory 
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response, activation of satellite cells, axonal regeneration and re-myelination, and fibrosis 
formation at the lesion site, and the precise underlying molecular mechanisms involved. 
Hence having an in-depth knowledge of the role of the integrity of the intra-muscular nerve 
in muscle regeneration after laceration is important for developing novel therapy to improve 
muscle repair at the onset of surgical repair.   
2)  LITERATURE REVIEW 
2.1)  Neurotrophic Factors 
Skeletal muscles initially develop in the absence of neural influence; however, their 
subsequent growth and survival depends on motor innervation. Many neurotrophic factors 
regulate the re-innervation of lacerated rat skeletal muscles, but in this study, the focus is on 
NT-4, GDNF, CNTF, IGF1, HGF, EGF and galectin-1 during the recovery of lacerated 
skeletal muscle post-surgery at the early (2-weeks) and late (12-weeks) phase. These 
influence both the myogenic and neurogenic recovery in lacerated muscles affected by a 
damaged intra-muscular nerve. These neurotrophic factors are also produced by neurons in 
the central and peripheral nervous systems, as well as the skeletal muscles, to regulate neural 
survival, axonal and dendritic outgrowth, synapse formation and plasticity, neuron cell 
migration and proliferation, satellite cell activation and myoblast proliferation and 
differentitation (Funakoshi et al, 1993).        
Neurotrophic factors do not stimulate muscle re-innervation in isolation. Through 
knockout studies illustrating endogenous actions or investigations using exogenous 
application, it is evident that the different cells can secrete the same neurotrophic factor or a 
single cell can synthesise multiple neurotrophic factors and each factor play unique role 
during different stages of re-innervation of skeletal muscle. There is overlapping expression 
of neurotrophic factors and their receptors after injury. Binding of the individual 
neurotrophic factor to specific receptor can activate several downstream intracellular 
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signaling cascades involving protein kinase A, phospholipase-C gamma, Ras, Mitogen-
activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI-3-K) (Sofroniew 
MV et al, 2001). Although some of these neurotrophic factors share common signaling 
transduction pathways in eliciting their biological actions, distinct mechanisms underlie their 
actions in different neurons and skeletal muscles. This significantly alters the repertoire of 
regeneration associated genes (RAGs) such as GAP43, beta-tubulin III, ATF3, Rho kinase 
and HN-1. While some neurotrophic factors can increase the RAGs expression, others 
inhibit the expression. The precise molecular mechanism for this differential RAG response 
is still unclear. The published findings about the signaling pathways and biological functions 
of the above neurotrophic factors are summarized as follows:   
2.1.1- NT-4  
NT4 is a member of the neurotrophin family. It is expressed by motor neurons and 
skeletal muscle (Escandon et al, 1994). NT-4 binds to the tropomyosin-related kinase 
receptor B (TrkB) with high affinity and the p75 neurotrophin receptor (p75 
NTR
) with low 
affinity (Huang EJ et al, 2001; Lee FS et al, 2001). Binding of the NT4 to TrkB receptor can 
activate several downstream intracellular signaling cascades involving protein kinase A, 
phospholipase-C gamma, Ras, Mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI-3-K) (Sofroniew MV et al, 2001). The activated signaling 
pathways mediate re-arrangement of the cytoskeleton and neurite formation, growth, 
survival and differentiation in various neurons (Lentz SI et al, 1999; Goldberg JL et al, 
2002). For example, it can activate CREB via the PI3K and MAPK pathways to promote 
axonal regeneration.  
NT4 is initially synthesized and secreted as 30-to 35-kDa precursor proteins. These 
are cleaved in the middle to release the biologically active 12-to 14-kDa C-terminal mature 
forms. The N-terminal domain allows for correct protein folding and secretion (Suter U et al, 
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1991). Both immature and mature NT4 are secreted in high abundance. In addition, neurons 
can secrete both full length and truncated forms of TrkB receptors. Mature NT4 dimerises 
and binds to specific TrkB with high affinity, to promote neuron survival whereas the 
immature NT4 preferentially binds to p75 to induce apoptosis.  Thus, the survival or death of 
neurons that co-express the TrkB receptor and p75 receptor depends on processing of the 
NT-4 ligands. 
The level of NT-4 is increased in the gastrocnemius and soleus muscles after sciatic 
nerve transaction (Funakoshi et al, 1993; Omura et al, 2005). NT-4 expression is particularly 
detected in slow type muscle fibres (Funakoshi et al, 1995). Furthermore, the role of NT-4 in 
muscle fiber type specification has been investigated. Injection of NT-4 into the soleus 
muscle of neonatal rats accelerates the fiber type transformation from fast to slow type 
myosin heavy chain. However, NT-4 fails to restore the normal course of this transformation 
in the denervated muscle, suggesting that its mechanism of action is via a retrograde signal 
to the motor neuron (Carrasco & English et al, 2003). At the neuromuscular junction, NT-4 
inhibits agrin-induced clustering of the acetylcholine receptors, mediated by the TrkB 
receptor (Wells et al, 1999). 
NT-4 also acts as an axonal guidance cue to direct the motor neuron to its target 
(Paves and Saarma et al, 1997; Tucker et al, 2001). It increases the synthesis of b-actin, 
peripherin and vimentin, as well as induces the asymmetric distributions of microtubular and 
actin-associated proteins to determine the direction of growth cone. Also, the use of NT-4 
containing conduits resulted in re-innervation of the soleus muscle (Simon et al, 2003). 
2.1.2- CNTF 
CNTF is expressed throughout the peripheral and central nervous systems, and also 
in skeletal muscle (Sendtner et al, 1994). While muscle–derived CNTF plays an important 
role in motor neuron survival (Arakawa et al, 1990), it also induces sprouting at the 
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neuromuscular junction after injury (Siegel et al, 2000). CNTF has a trophic function in 
denervated muscles as it can attenuate atrophy and reduce loss of twitch and titanic tensions 
associated with denervation (Helgren et al, 1994). It also controls protein turnover in muscle 
(Wang and Forsberg et al, 2000), regulating the synthesis of enzymes such as 
acetylcholinesterase (Boudreau-Lariviere et al, 1996). Interestingly, recent studies suggest 
that CNTF can also modulate the differentiation of muscle satellite cells (Chen X et al, 
2005) and therefore plays a role in muscle regeneration via activation of STAT3 (Kirsch et 
al, 2003).  
It binds to CNTF receptor which has a glycosyl-phosphatidyl-inositol-anchor (GPI) 
(Grotzinger et al, 1997). The CNTF receptor is composed of an extra-cellular CNTF-binding 
subunit, CNTF receptor-α, and two transmembrane proteins, gp130 and leukemia inhibitory 
factor receptor-b. Through this receptor complex, CNTF elicits its biological actions 
primarily via the JAK/STAT3 signaling pathway, but it can also activate the PI3K and 
MAPK pathways.    
2.1.3- GDNF 
GDNF is abundantly expressed by skeletal muscle (Nagano and Suzuki, 2003), 
motor neurons and sensory neurons. It protects the survival and promotes the axonal 
regeneration of both motor neurons and sensory neurons (Matheson et al, 1997) after nerve 
transaction (Burazin and Gundlach et al, 1998). It is important for the development and 
function of synaptic connections. GDNF is constitutively supplied to the neuromuscular 
junction during postnatal development and into adulthood, suggesting its importance in 
maintenance of the junction (Nagano and Suzuki, 2003). After denervation, there is an up-
regulation of GDNF levels in the muscle. Altered production of GDNF in muscle may be 
responsible for activity-dependent remodeling of the neuromuscular junction (Wehrwein EA 
et al, 2002). Over-expression of GDNF in skeletal muscle induces multiple endplate 
20 
 
formation and results in hyper-innervation (Zwick M et al, 2001). This is proven using 
transgenic mice which over-expressed GDNF under the control of the myogenin promoter, 
where re-innervation is enhanced in the mice after nerve injury but the muscles were not 
functional due to poly-innervation (Gillingwater TH et al, 2004).  
GDNF signals through a multi-component receptor complex that comprises a 
glycosyl-phosphatidyl-inositol-anchored GDNF Family Receptor-1 (GFR-a1) and a Re-
arranged during transfection Trk receptor (RET).  Binding of GDNF to the GFR-a1 and RET 
can activate the PI3K and MAPK pathways to regulate survival, neurite outgrowth and 
synaptic plasticity. GDNF can also signal through the neural cell adhesion molecule, 
NCAM, independently of RET. By binding to NCAM, GDNF stimulates axonal growth in 
hippocampal and cortical neurons via up-regulation of GAP-43 and BII-tubulin.   
3) AIM 
The first aim was to study the regenerative response at the lesion site of a lacerated 
muscle where both the muscle and intra-muscular nerve are damaged, with main emphasis 
on the expression profiles of neurotrophic factors, atrophic factors and fibrosis factors 
during the early phase (2-weeks) and late phase (12-weeks) of muscle repair using the 
medial gastrocnemius of adult male Sprague-Dawley rats. At 2-weeks denervation was 
reversible, while after 12-week, muscle denervation would be permanent and muscle 
atrophy would be irreversible.  
Another goal of the study is to determine if there are specific endogenous anti-fibrosis, 
anti-atrophic and anti-re-innervation targets to improve muscle and nerve regeneration in the 
early phase post-laceration, and so we investigated several candidate genes and proteins to 
assess their mRNA and protein expression levels in various lacerated muscle models 




The rationale for selection of targets to assess the fibrosis, atrophy, myogenesis, 
isometric contraction, intra-muscular nerve regeneration in this lacerated skeletal model was 
based on published literature reports on keloid (Ong CT et al, 2010) and lacerated muscle 
injury models. These factors were to assess the severity of fibrosis formation at the lesion 
site and to investigate the extent of reversible and irreversible muscle atrophy and 
denervation at the 2 time points in five different treatment groups. The correlations between 
the expression trends of selected markers for fibrosis, atrophy, myogenesis, isometric 
contraction and intra-muscular nerve regeneration in our lacerated rat skeletal muscle model 
was detected using the Pearson correlation analysis. The targets are classified into several 
categories based on their biological functions stated in the literature. 
4) STUDY HYPOTHESIS 
The null hypothesis in this study was that if the integrity of the intramuscular nerve 
remains intact (PN) or is repaired (RN) in a lacerated muscle, the muscle repair across the 
laceration will be improved by 12-weeks compared to the denervated skeletal muscle (DN). 
The alternative hypothesis is that preserving or repairing the intramuscular nerve in lacerated 
muscles will not improve the muscle repair after 12-weeks. In either case, neurotrophic 
factors would be secreted from the damaged nerve and lacerated muscle that could direct the 
neurogenic and myogenic recovery across the lacerated site of the cut muscle.   
[Experimental note: In simulating an intact intramuscular nerve, the intramuscular nerve was 
preserved without damage during the laceration. In simulating a repaired intramuscular 
nerve, the intramuscular nerve was crushed preserving the nerve sheath but damaging the 
axons within. In actual clinical practice, it is the nerve sheath that is micro-anastomosed 
only, not the axons, during nerve repair and therefore this could simulate either a re-




5) MATERIALS AND METHODS 
5.1) Animal Model 
The Ethics Committee of the Animal Holding Unit (IACUC) at the National University of 
Singapore (NUS) approved and monitored the animal surgery protocol (Protocol 
No:112/08). All animal care and surgery were in accordance with the policies at the NUS, 
governing the use and care of animals in research and teaching. Experiments were 
performed on 500g adult SD rats (12-weeks old). All rats were individually housed in a 
thermo-neutral environment, given food and water ad libitum. The left medial gastrocnemius 
muscle was chosen as the muscle model as the medial gastrocnemius is a large muscle and is 
only part of three muscles involved in ankle flexion, together with the lateral gastrocnemius 
and soleus. Therefore sacrificing of this muscle in this model will not totally disable the 
animal’s mobility. The muscle is also innervated by only one nerve (a branch from the tibia 
nerve), which makes micro-surgical denervation, repair and subsequent monitoring of 
isometric contractile properties feasible (Larkin LM et al, 2000). The right limb was used as 
the control/sham (PosC). 
5.2) Surgery 
All surgical procedures were performed by the same lab officer (ZouYu), under 
aseptic conditions. Rats were anaesthetized with intra-peritoneal injection of 3:2 ratio of 
ketamine and xylazine (0.2mL/100g); placed in a prone position. The lower limb was 
extended at the hip, knee and ankle to expose the popliteal fossa. After shaving, a skin 
incision on the posterior aspect of the mid thigh to about 1cm proximal to the calcaneum 
was made. The skin flap was dissected, exposing the popliteal fat and the two bellies of the 
gastrocnemius muscle (MG). The bellies are enclosed in a layer of fascia that formed a raphe 
in the midline, between the two bellies, joining distally at the common calcaneal tendon. The 
popliteal vein, artery and the sciatic nerve and branches were isolated, exposing the nerve 
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branches arising from the tibia nerve, to the bellies of the gastrocnemius and soleus. The 
nerve to the medial belly of the gastrocnemius was seen passing obliquely to its entry point 
(motor point) between the proximal quarter and distal three quarters of the belly. This branch 
measured an average 5-6 mm in length, and was on average about 0.4-0.6mm in diameter. 
For the completely lacerated muscle model, the whole muscle belly of the MG was divided 
transversely using a sharp scalpel blade, 2-3mm distal to the entry point of the nerve branch. 
Distal to the laceration site, the nerve was seen at 10X magnification to bifurcate into three 
branches within the distal segment of the cut muscle belly. The concomitant cut nerve in the 
proximal segment was observed to have 2 to 3 fascicles. This is a clean-cut laceration model. 
To avoid variations in muscle damage, a sharp laceration was used over a blunt laceration. 
The blunt model would have increase damage away from the lacerated site and would have 
unknown factors involved that can affect the results. 
5.3) Experimental Groups 
Five groups were assessed at 2-weeks and at 12-weeks post-repair. The groups were as 
follows: 
(a) Denervated Intramuscular Nerve (DN) Model: A through-thickness laceration of 
the MG was done via a sharp dissection across the proximal third of the muscle belly, 
distal to the entry point of the branch from the tibial nerve (Fig 1B). 
(b) Preserved Intramuscular Nerve (PN) Model: The nerve branch entering the MG 
was traced intra-muscularly, and the muscle was lacerated as in (a), but care will be 
taken to preserve the intra-muscular nerve distal to the motor point (Fig 1B). 
(c) Re-innervated Intramuscular Nerve (RN) Model: The MG was lacerated as in (b), 
and the intra-muscular nerve was concomitantly crushed with an arterial forcep to 
preserve the nerve sheath but damage the axons. No micro-anatomosis was done. 
This model was to simulate either a re-innervated nerve, or a repaired nerve (Fig 1B). 
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Electrical stimulation was used to confirm that there was axonal damage, while 
integrity of the nerve sheath was also assessed to confirm continuity.   
(d) Negative Control (NegC) Model: The MG was lacerated as in (a), and the 
peripheral branch from tibia nerve proximal to the motor point was cut and ligated to 
prevent re-innervation. NegC is a lacerated muscle with the peripheral nerve cut and 
ligated (i.e the extra-muscular nerve branch that comes from the tibia nerve before it 
enters the muscle). Similar to DN, but this is with the ligated peripheral nerve – 
partial denervated with no possibility of re-innervation or sprouting coming from this 
nerve stump. Any nerve sprouts would therefore have to come from some other 
neighbouring nerve branch. 
(e) Positive Control (PosC) Model: The right limb of the rat, with no surgery done on 
the MG was the Sham operation.  
(f) Modified Kessler suture is used in all groups (Fig 1A) because it gives the best 
morphologic and functional healing for management of lacerated skeletal muscle 
without immobilization, and it ensures that any molecular and histological 
differences in fibrosis and atrophy among the treatment groups is solely due to 
integrity of the intra-muscular nerve. Suturing the edges of laceration between two 
myofibers will reduce the size of the gap and reconstruct the framework for the basal 
lamina to regenerate. This does not prevent the initial muscle necrosis, fibrosis and 
the acute inflammatory response induced by the clean cut of the muscle belly.  
Immobilisation of lacerated skeletal muscle post-surgery will delay the 
healing process. It can lead to the development of excessive deep scar between two 
ruptured myofibers, inhibit angiogenesis between two muscle stumps and result in 
significant muscle atrophy. This prohibits a fair comparison of the expression 
profiles of selected markers between the treatment groups and the control group (not 
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Figure 1A Schematic representation 
of modified Kessler suture technique. 
It consists of a two-strand repair with 
use of a single knot within the repair 
site. The steps are as follows: 
(1) suture needle is inserted into the 
side of cut muscle end, 1cm from the 
severed muscle edge, and is passed 
longitudinally out of the muscle edge 
(2) needle is then passed into the 
corresponding severed muscle cut end 
and is passed longitudinally 1cm out 
of the side of the muscle (3) suture is 
then re-inserted a few mm distal to its 
exit point (no locking), and is directed 
in a cross-wise fashion to exit in the 
middle of the muscle laeration site (4) 
suture is re-introduced into the 
opposite muscle segment and 
continues across in crossing direction, 
and is brought out on the opposite 
muscle side (1cm from the laceration 
site) (5) suture is introduced a few 
Figure 1B Experimental lacerated skeletal 
muscle models. A transverse complete 
laceration was simulated at the proximal 
quarter of the muscle belly just below the 
entry point of the peripheral nerve branch 
supplied by the tibial nerve (N). The 
peripheral nerve branch enters the muscle at 
the epimysium and becomes the main 
intramuscular nerve branch (im-b). The 
three lacerated skeletal muscle groups 
simulated were DN, a denervated skeletal 
muscle, where the im-b was also cut, RN, a 
re-innervated skeletal muscle group, where 
the im-b was crushed with the epineurium 
intact, and PN, where the im-b was 
preserved intact. All muscle belly 
lacerations were repaired with core sutures 




mm distal (no locking) and is directed 
longitudinally across the laceration 
site (6) suture is then passed back 
crossing the middle of the laceration 
site to exit next to the free muscle 
edge (7) make sure the slack is 
removed with each pass of the suture 
(8) tighten all the sutures before a 
knot is tied (9) bury the knot inside 
the repair site  
 
                      
 
5.4) Histology 
The MG from both limbs in all rats was then harvested under anaesthesia, and the 
wet weights measured. The lacerated MG was divided into 3 parts: the mid segment which 
included the site of laceration (fibrotic zone), the distal segment which was distal to the 
laceration site and a proximal segment which was proximal to the laceration site. Only the 
mid segments for all cases were used in histology and immunohistochemistry staining, RNA 
extraction for real-time PCR analysis, protein extraction for western blot experiments. This 
is because the proximal and distal segments were reserved for micro-array work in a 
separate project. The biopsies were snapped frozen in liquid nitrogen, kept in cryovials, and 
later stored in -80°C freezer. Selected biopsies were later fixed in formalin and paraffin-
embedded. Serial sections of 8-um thick were cut from the paraffin blocks and mounted on 
Matsunami adhesive slides (Unison) for hematoxylin and eosin, and Masson Trichrome 
staining (Merck). 
5.5) Immunohistochemistry 
 8-µm sections were cut in series from formalin fixed paraffin embedded rat skeletal 
muscle samples. Paraffin sections were dewaxed in 3 changes of xylene, hydrated in 
descending grades of ethanol, followed by a short 5min rinse in running tap water. Antigen 
retrieval was performed using dedicated histology microwave oven, Milestone Mega T/T, 
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according to the manufacturer’s protocol for each antibody (Table 1).  
Table 1. Milestones Mega T/T Antigen Retrieval program. 
Step Time (min) Power  (W) Temperature (˚C) 
1 20 600 80 
2 0.5 400 85 
3 20 200 88 
4 1 200 91 
5 20 190 96 
6 20 150 98 
 
All sections are washed in running tap water for 10 min after antigen retrieval. The 
Dako Envision+ kit was used for the subsequent IHC steps. Briefly, endogenous peroxidase 
was blocked in 3% hydrogen peroxide for 30min, and then the slides were washed in 1X 
TBS-Tween-20 X 3 times, followed by incubation with primary antibody. The secondary 
antibody was applied after rinsing the slides. Slides were washed sequentially with 1X TBS-
Tween-20 and incubated with DAB for 5min. Next, the slides are washed with water to 
quench the DAB, followed by dehydration in ascending grades of ethanol, drying in the 
oven for 10min and then clearing in xylene before been mounted with coverslips using 
Depex (Merck). Non-immunised host serum of the respective primary antibody was used for 
negative controls.  We did not use frozen tissue sections for immunohistochemistry staining 
because the cryostate in the lab was damaged. 
5.6) SDS-PAGE and Western Blot 
Frozen rat skeletal muscle was homogenized with a hand-held Polytron in lysis 
buffer made of 8M urea, 2M thiourea, 4% CHAPS, 0.1M DTT, 0.025M Tris and 0.20M 
glycine pH8.3.  This step is done on ice at 20,000rpm for 5 min, with 30sec break for each 
min. The lysates were then centrifuged at 14,000g for 5min at room temperature, after which 
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the supernatant was transferred to new tube and the protein concentration of the total tissue 
lysate was estimated using the GE 2-D Quant kit. We used BSA as the protein standard in 
estimation of protein amount because it is cheaper than recombinant proteins, the protocol 
has been optimized for many other protein targets in other projects and the proteins of 
interest in this project are not in the immunoglobulin family. The recipe for casting SDS-
PAGE gels with added glycerol is listed in Appendix 3. Glycerol in the gels enhances the 
separation of proteins with high molecular weight and prevents the gels from curling during 
electro-transfer. 
10µg/uL of protein were mixed with appropriate volume of SDS-denaturing loading 
buffer (8M urea, 2M thiourea, 5% SDS, 0.075M DTT, 0.01% bromophenol blue) in the ratio 
1:10 (v/v) (Blough E et al, 1996), then resolved on a mini SDS-PAGE gel at constant 125V 
for 1h 30min, then the voltage was increased to 250V to flush out the bromophenol dye of 
the gel. The proteins on the gel are then transferred onto nitrocellulose membranes (Bio-
Rad) at constant 100V for 2h in cold room. The amount of protein loaded per well is below 
30ug/uL because the skeletal muscle contains high levels of myosin heavy chains and other 
high molecular weight proteins such as titin and nebulin which are difficult to resolve 
properly in non-gradient mini SDS-PAGE gels. High loading amount of such high molecular 
weight proteins will lead to smearing of bands on the nitrocellulose membranes after electro-
transfer. After washing the membrane with 1X TBS-Tween-20 for 10min, followed by 
rinsing with MQ water, the membrane was blocked with 5% non-fat milk in 1X TBS for 2h 
at room-temperature. Then the membrane is washed with 1X TBS-Tween-20 for 10min X 5, 
before incubation with the desired primary antibody for 1h at room temperature. The 
membrane was then rinsed 5 times, 10min each, with 1X TBS-Tween-20 before the 
secondary antibody-conjugated with HRP was applied. The blots were visualized with ECL 
Plus chemi-luminescence detection kit according to manufacturer’s instruction (Amersham). 
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Equal sample loading was monitored using mouse monoclonal anti-rat alpha-tubulin.  
Alpha-tubulin was chosen as it is expressed by both fast and slow myofibers, and it is 
present in both developing and adult muscle fibers. In addition, it is commonly used as a 
loading control in immunoblotting of muscle proteins and hence it is a good choice for 
comparison. Optical densitometry quantification of the respective intensity of the 
immunoblot bands was done using GelPro v4.5. 
5.7) RNA Extraction 
Total RNA was extracted from frozen MG muscle using the Qiagen Mini-RNA for 
fibrous tissue kit, following manufacturer’s instruction. The RNA concentration was 
determined by optical density at 260nm using NanoDrop. The purity of extract was 
confirmed based on OD260-to-OD280 ratio of 1.8 to 2.0. The RNA integrity was assessed 
by agarose gel electrophoresis and GelRed staining of 1g total RNA. Only intact RNA 
samples were used for the reverse transcription and subsequent real-time PCR analysis. 
5.8) Reverse Transcription 
 Reverse transcription was performed with High Capacity cDNA Archive kit (ABI) and the 
ABI 2720 Gene Amp thermal cycler, using 1g RNA in 20µL reaction volume (Tables 2A 
and 2B).  
Table 2A. First strand cDNA synthesis reaction mix 
Component Volume (uL) 
Mix A: 
RNA (1ug/uL) 1.0 
10X Random hexamers 2.0 
25X dNTPs (100mM) 0.8 




Load Mix A into thermal cycler and denature the RNA at 65˚C for 10 
min, then incubate the Mix A at 4˚C for 10 min prior adding Mix B on 
ice-bath. Vortex and spin down all reaction mixes before loading them in 
thermal cycler to start the reverse transcription. 
Mix B: 
10X Reverse transcriptase buffer 2.0 
Multiscribe reverse transcriptase 1.0 
RNAse Inhibitor 1.0 
Total 4.0 
 
Table 2B. High capacity reverse transcription protocol 
Thermal 
Cycler 




1. Activation of random 
hexamers annealing to 
RNA 
10 25 
 2. Activation of reverse 
transcriptase 
120 60 
 3. Inactivation of reverse 
transcriptase 
5 85 
  4.  Cooling infinity 4 
 
5.9) Real-time PCR 
1L of cDNA (100 g) was then mixed with respective TaqMan MGB probes and 
1X universal TaqMan PCR mastermix (ABI) for real-time PCR analysis on the 7500HT real-
time thermal cycler (ABI), accordingly (Tables 3A and 3B).  
 
Table 3A. Real-time PCR reaction mix 
Component Volume (L) 
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Taqman Universal PCR Mastermix, no UNG, 2X 10.0 
20X TaqMan Gene Expression Assay Mix 1.0 
cDNA (100ng), diluted in nuclease-free water 9.0 
Total        20.0 
 
Table 3B. Real-time PCR: thermal cycling protocol 
Thermal Cycler Step Time Temperature (˚C) No of cycles 
7500HT, ABI 1: Taq Polymerase Activation  10 min 95 1 
 2: DNA Denaturation 15 sec 95 40 
 3: Annealing and Extension 1 min 60 40 
 
Two negative controls were performed for each sample. In the first negative control, 
the reverse transcriptase was omitted in the RT-PCR reaction mix. Under these conditions, 
formation of a product indicates either genomic DNA contamination or reagent cross-
contamination. The second negative control consisted of no RT primers when the RNA was 
reverse-transcribed. This ensures that the cDNA obtained is not due to self-priming of RNA. 
Each sample was analysed in triplicates following manufacturer’s instruction, and lamin A 
was the endogenous control. Lamin A was chosen as a control as it is expressed by both fast 
and slow myofibers as well as present in both developing and adult muscle fibers. Its 
expression level is also within the medium abundance range so using it as a denominator in 
the relative quantification equation will not mask the genes that are expressed at very low 
levels or high levels in both regenerating and mature muscle fibers. The relative 
quantification (RQ) equation is given below:  
RQ = 2 – (Ct) 
[where Ct = (Ct of target gene) treatment ─ (Ct of target gene) control / 
(Ct of endogenous gene) treatment   ─  (Ct of endogenous gene) control] 
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5.10) Statistical Analysis 
  Gene expression results were analysed with Sequence Detection Software v1.4. 
Average Ct values with standard error greater than 0.3 are omitted, tests are repeated. RQ 
values are shown in means and SD, n=3 per treatment group. Optical densitometry 
quantifications of the respective intensity of the protein bands were done using GelPro v4.5 
and expressed as means ± standard errors in arbitrary units. Statistical significance between 
treatment groups and the control were calculated using SPSS v1.9 with one-way analysis of 
variance (ANOVA) and Scheffe’s post-hoc test, where *p<0.05, for both gene and protein 
expression assays. For real-time PCR, the calibrator sample was cDNA reverse transcribed 
from the RNA extracted from the normal medial gastrocnemius muscle from the opposite 
limbs. All RQ values were then represented as fold-changes ± standard error. There is no 
significant statistical difference for lamin A gene expression between the treatment groups 
and the controls (see Appendix 6), and the same applies to that for alpha-tubulin protein 
expression (see Appendix 7). Pearson's correlation coefficient (r) was also calculated to 
measure the linearity of the relationship between all gene and protein markers. All statistical 
tests were two sided with statistical significance set at p < 0.05 (Appendix 12). 
6) RESULTS 
6.1- Histomorphology Comparison between PN and DN 
In all groups, the lesion site remains fibrotic at 12-weeks post-surgery (Fig. 2). 
Denervation induced significant decrease in the wet weight of the medial gastrocnemius. At 
2-weeks post-surgery, all the groups showed a decreased wet weight of about 60% of the 
control value. After 12-weeks, the PN regained 80% of the wet weight of the control level 
while DN achieved only 40% of the control value and RN attained about 70% muscle mass 
of the normal muscle. Differences in the cross-sectional area of scar region and size of 
myofibers were also noted between the PN, RN and DN. The primary aim of this histo-
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morphologic study was to determine these differences between lacerated muscles which had 
its intramuscular innervations preserved (PN) or damaged (DN).  DN showed highly random 
(mosaic) pattern of immature muscle fibers with small size and central nuclei, and extensive 
scarring at lacerated site, while PN had more mature, fully differentiated adult muscle fibers 
with large cross-sectional area and multiple peripheral nuclei, and minimal fibrosis at the 
lesion site. This indicates that DN, RN and PN have distinct histology features of muscle 
regeneration, arising from important differences at the gene expression level of unique 
targets. 
 
Figure 2. Muscle Atrophy. At 2-weeks after repair, all muscles had a significant reduced 
muscle mass. Masson’s Trichrome staining at the lesion site (arrows) showed the repair site 
at 2-weeks with DN having a discontinuity, while RN and PN having its cuts ends bridged 
differentially by connective and muscle tissue. At 12-weeks the cut lesion was less visible, 
yet DN still continued to have a poor repair. (Longitudinal section, original magnification: 











6.1.1- Immunohistochemistry Staining for Intermediate Filaments, Galectin-1 and R-
spondin-1 
We assessed if the damaged intramuscular nerve in a lacerated muscle contributed to 
poor muscle regeneration. At 2-weeks post-laceration, there was progressive muscle atrophy 
and fibrosis in both DN and PN, marked by myofiber size reduction and large collagen 
deposits at laceration site. Desmin and vimentin were weakly expressed by proliferating 
myoblasts and immature myotubes in DN but not as obvious in PN. Vimentin was also 
highly expressed by mononuclear immune cells and fibroblasts in the fibrotic zone. Desmin 
expression was up-regulated in proliferating myoblasts and mature myofibers but vimentin 
expression ceased completely after 12-weeks in both DN and PN. Nestin was moderately 
expressed by proliferating myoblasts in both groups, co-localised with desmin and vimentin 
at 2-weeks. Minimal nestin expression adjacent to muscle-tendon junctions of mature 




                    
Figure  3. Immunohistochemistry of desmin and nestin expression. Desmin and nestin were 
expressed by proliferating myoblasts and immature myotubes in DN and PN. Nestin 
expression co-localised with desmin at 2-weeks post-repair. 
 
 
R-spondin-1 was strongly expressed by proliferating myoblasts and immature 
myotubes at 2-weeks in PN, more than DN (Fig. 4). No R-spondin-1 expression was 
detected in mature myofibers after 12-weeks in both groups and was demonstrated by their 
protein assays (Fig. 5). Galectin-1 was expressed as organised diagonal rows of large spots 
in PN, while in DN, it was presented as random diffuse dots (Fig. 6).  In addition, fibroblasts 
and macrophages at the fibrotic zone also displayed both strong galectin-1 and R-spondin-1 




    
Figure 4. Immunohistochemistry of galectin-1 and r-spondin-1 expression at the lesion site 
For DN, strong galectin-1 and r-spondin-1 expressions in spindle-shaped fibroblasts (white) 
at lacerated site, and also in macrophages with plump nuclei (black arrows). While for PN, 






Figure 5. Immunohistochemistry and western blot of R-spondin-1 expression. R-spondin-1 
was strongly expressed in macrophages (black arrows with M), fibroblasts (white arrows 
with F), myoblasts and immature myotubes (red arrows) in DN at 2-weeks post laceration. 
Optical densitometry quantification of R-Spondin-1 protein expression levels normalized to 
alpha tubulin, using GelPro v4.5 (arbitrary units) was obtained from three independent 
experiments with 3 rats. P-values were calculated by Scheffe’s post-hoc test, where p<0.05 
is considered statistically significant. (* - indicates significant difference (p<0.05) to 
Positive Control, Csham).  
 
 
The strong expression of galectin-1 at 2-weeks for both PN and DN suggest that the 
myogenic repair process was progressing well (Fig. 4), while at 12 weeks (Fig. 6) the higher 
and dis-organised expression of galectin-1 in DN is linked to slow myofiber and axonal 
recovery. It also reflects the random re-innervation of the myofibers distal to the lesion site 
amidst a mass of collagen scar. The re-innervation of myotubes following muscle injury is 






Figure 6. Immunohistochemistry and western blot of galectin-1expression. Comparing DN 
and PN at 12-weeks post-repair. Galectin-1 was expressed as organised diagonal rows of 
large spots in PN, while in DN, it was presented as random diffuse dots (arrows). Optical 
densitometry quantification of Galectin-1 protein expression levels normalized to alpha 
tubulin, using GelPro v4.5 (arbitrary units) was obtained from three independent 
experiments with 3 rats. P-values were calculated by Scheffe’s post-hoc test, where p<0.05 
is considered statistically significant. (* - indicates significant difference (p<0.05) to 











6.2- Gene and Protein Expression Profiles 
6.2.1- Comparing PN, RN, DN and NegC against the sham control, PosC 
  
 The gene expression data is presented as mean RQ values based on 3 samples, and 
for each sample triplicate datasets. The housekeeping gene used for each real-time PCR run 
is lamin A.  The protein expression data is presented as means based on optical densitometry 
quantification against -tubulin, which is as loading control.  As the study looks at both 
myogenic and neurogenic recovery in lacerated muscles affected by a damaged intra-
muscular nerve, the candidate markers are divided into 5 categories (Table 4).  
Table 4. Classification of candidate markers  
 Category Gene or protein markers 
1 Fibrosis markers collagen-1, aggrecan, vimentin, -Smooth Muscle Actin 
 pro-fibrosis TGF2, galectin-1, CTGF, R-spondin-1, GDNF, Sonic 
hedgehog, IGF1, HGF, myostatin, NT4 
 anti-fibrosis decorin, follistatin, EGF, PGC-1, AMPK-1Sirt1, CNTF 
2 Atrophy markers atrogin-1, MuRF-1, complement-3 
 pro-atrophy  myostatin, myogenin,  AMPK-1 
 anti-atrophy  calpain-3, IGF1, NT4, GDNF, CNTF, PGC-1, 
Sirt1,decorin, follistatin 
3 Myogenesis markers  myoD, myogenin, Mef2a, desmin 
 pro-myogenesis galectin-1, decorin, follistatin, IGF1, HGF, EGF, Sonic 
hedgehog, NT4, GDNF, CNTF, PGC-1, R-spondin-1 
 anti-myogenesis TGF2, myostatin, CTGF, AMPK-1 
4 Isometric contraction 
markers 
pro-slow myosin heavy  chain 
and slow troponin-I (anti-fast 
myosin heavy chain and fast 
troponin-I)  
anti-slow myosin heavy chain 
and slow troponin-I (pro-fast 
myosin heavy chain and fast 
troponin-I) 
anti-fast and anti-slow myosin 
heavy chain, anti-fast 
troponin-I and anti-slow 
troponin-I 
slow troponin-I, fast troponin-I, fast myosin heavy chain, 
slow myosin heavy chain, embryonic myosin heavy chain 








TGF2, complement-3, MuRF-1, atrogin-1 
5 Intra-muscular nerve 
regeneration marker 
GAP43 
 pro-axonal regeneration  IGF1, HGF, galectin-1, NT4, GDNF, CNTF, follistatin, 
decorin, EGF, Sonic hedgehog, HN1 
 anti-axonal regeneration collagen-1, aggrecan, TGF2, complement-3, CTGF 
6 Signaling pathway markers 1) MAPK kinase pathway: p38, Erk1, Erk2 
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2) SMAD pathway: SMAD2, SMAD3 
 
Each category is further divided into 2 smaller groups, pro- and anti-, depending on 
specific function of the selected target with respect to the phenotype based on published 
reports. A few targets will appear in more than one category due to their different functions 
in different cells and physiological contexts. 
6.2.2- Fibrosis markers  
Collagen-1, Aggrecan, Vimentin, -Smooth Muscle Actin 
 
The expression level of collagen-1 and aggrecan (Fig 7A) was significantly up-
regulated in all 4 groups at 2-weeks post-laceration compared against the control 
(p<0.05). DN and RN had the highest collagen-1 expression level (> 20-fold than the 
control). After 12-weeks, collagen-1 and aggrecan were down-regulated in all groups, 
but the expression level remained higher than the control (p>0.05).  NegC and DN had 







Figure 7A. Fold changes (normalized to Lamin A) of Collagen-1, Aggrecan and Vimentin. 
ANOVA and post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified 
the homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats (n=3); p-
values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC). 
                 
The expression level of the intermediate filament, vimentin was significantly up-
regulated in all groups at 2-weeks post-laceration compared against the control. In PN, 
vimentin expression level were 3.0-fold greater than the control (p<0.05).  After 12-
weeks, vimentin was down-regulated in all, but in DN where the expression remained up 
by >2.0-fold greater than the control (p<0.05). Immunoblotting results showed that 
vimentin and -SMA protein expression level (Fig. 7B), both markers for the 
myofibroblastic phenotype, were significantly up-regulated in all groups at 2-weeks post-
laceration compared against the control (p<0.05). After 12-weeks, vimentin was down-
regulated in all but DN, where its protein level remained highly expressed (p<0.05), 
while -SMA remained higher than the control (p<0.05). The highest mean level of 
vimentin and -SMA were in PN at 2-weeks and 12-weeks post-laceration, respectively, 





Figure 7B. Optical densitometry quantification of myofibroblast markers - -SMA and 
vimentin protein expression levels normalized to alpha tubulin, using GelPro v4.5 (arbitrary 
units) at 2-weeks (dark bars) and 12-weeks (lighter bars). Data was obtained from three 
independent experiments with 3 rats. p- values were calculated by Scheffe’s post-hoc test, 
where p<0.05 is considered statistically significant. (* - indicates significant difference 
(p<0.05) to Positive Control, CSham). 
 
6.2.2.1- Pro-fibrosis markers  
TGF2, Galectin-1, Myostatin, CTGF, HGF, R-spondin-1, NT4, GDNF, IGF1, Shh 
 
  
The expression level of TGF2 was significantly up-regulated in PN and DN at 2-
weeks post-laceration compared against the control (p<0.05). DN has the highest TGF2 
expression level, about 0.4-fold greater than the level of the control. The expression level of 
EGF was initially down-regulated in all PN, RN and DN, but not in NegC, at 2-weeks post-
laceration (Fig. 15A, p<0.05). After 12-weeks, TGF2 was down-regulated to the baseline 
level of the control in all groups (p>0.05), except in DN where TGF2 remained high, about 
0.2-fold higher than in control (Fig. 8A).               
The expression levels of galectin-1 and myostatin were up-regulated in all 4 groups 
at 2-weeks post-laceration compared with the control (p>0.05) (Fig. 8A). In PN, the 
galectin-1 expression level is about 0.60-fold greater than the control (p<0.05). After 12-
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weeks, galectin-1 expression level in all groups remained higher than the control (p<0.05) 
with PN having a 0.11-fold greater than the control (p<0.05); while myostatin further 
upregulated remaining higher than the control (P<0.05). In DN, myostatin protein expression 





















Figure 8A.   Fold changes (normalized to Lamin A) of TGF2, Galectin-1, myostatin and 
EGF. ANOVA and post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair 
identified the homogenous sub-sets that were not significantly different (See Appendix 4). 
Data is expressed as means ± SD of three independent experiments obtained with 3 rats 
(n=3); p-values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered 
statistically significant. (* - indicates significant difference (p<0.05) to Positive Control, 
PosC).  
 
Immunoblotting results (Fig. 8B) for galectin-1 protein level showed significantly 
up-regulated in PN, DN and RN at 2-weeks post-laceration (p<0.05). After 12-weeks, 
galectin-1 protein expression was down-regulated in all groups close to baseline level 
(p<0.05). The highest mean level of galectin-1 was present in PN at 2-weeks post-laceration 
compared with the control (p<0.05). TGF2 and CTGF protein level were also significantly 
up-regulated in PN, DN and RN at 2-weeks post-laceration compared against the control 
(p<0.05). After 12-weeks, TGF2 and CTGF level in all groups remained higher than 
control (p<0.05). The data showed that the highest mean level of TGF2 was present in DN 
and for highest CTGF in RN at 12-weeks (p<0.05).  The stronger expression of galectin-1 at 
2-weeks for both PN and DN suggest that the myogenic repair process was progressing well 
while at 12 weeks, the higher and disorganised expression of galectin-1 in DN is linked to 
slow myofiber and axonal recovery. It also reflects the random reinnervation of the 
myofibers distal to the lesion site. The re-innervation of myotubes following muscle injury is 




Figure 8B Optical densitometry quantification of Galectin-1, TGF2 and CTGF protein 
expression levels normalized to alpha tubulin, using GelPro v4.5 (arbitrary units). Data was 
obtained from three independent experiments with 3 rats. P-values were calculated by 
Scheffe’s post-hoc test, where p<0.05 is considered statistically significant. (* - indicates 
significant difference (p<0.05) to Positive Control, CSham). 
 
Immunoblotting of R-spondin-1 at 2-weeks (Fig. 8C) showed significantly up-
regulation in all groups compared with the controls (p<0.05). After 12-weeks, R-spondin-1 
protein expression level was down-regulated in all groups, but remained higher than the 
control (p<0.05). The highest mean level of R-spondin-1 were present in PN at 2-weeks 
post-laceration compared with the control (p<0.05). 
  At 2-weeks post laceration (Figure 12A), IGF1 expression levels were upregulated in 
all groups, except in NegC (P<0.05). After 12-weeks, IGF-1 was down-regulated back to the 
control levels. At 2-weeks (Fig. 12B), NT-4 was up-regulated in all groups except for NegC 
(p>0.05), with PN having the highest NT-4 level (> 14.0-fold). Similarly, GDNF was up-
regulated in all groups (p<0.05) with DN having the highest GDNF expression level (>45-
fold, p<0.05). The expression levels of HGF were significantly up-regulated in all groups at 
2-weeks post-laceration (p<0.05). After 12-weeks, HGF was down-regulated, but remained 
higher than the baseline level of the control in all groups (p<0.05). RN had the highest level 
of HGF (>1.7-fold, p>0.05). The mRNA expression level of Shh (Fig. 17) were up-regulated 
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in all 4 groups at 2-weeks post-laceration compared against the control (p<0.05). PN has the 
highest Shh expression level (about 8.0-fold greater, p<0.05).  After 12-weeks, Shh were 
down-regulated in all groups, but remained higher than the baseline control (p<0.05). Shh 
expression is the highest in RN (p<0.05).        
 
 
               
Figure 8C. Optical densitometry quantification for R-spondin-1 protein expression levels 
normalized to alpha tubulin (arbitrary units). Data was obtained from three independent 
experiments with 3 rats. p- values were calculated by Scheffe’s post-hoc test, where p<0.05 
is considered statistically significant. (* - indicates significant difference (p<0.05) to 
Positive Control, CSham). 
 
6.2.2.2- Anti-fibrosis markers  
 Decorin, Follistatin, EGF, PGC-1, AMPK-1Sirt1, CNTF  
The expression level of follistatin and decorin were up-regulated in all 4 groups at 2-
weeks post-laceration (p>0.05) (Fig. 9). DN has the highest follistatin expression levels (18-
fold at 2 weeks; 7-fold, at 12-weeks, p<0.05). Decorin was down-regulated in all groups at 
12-weeks, except for PN where it remained higher than the control by 11-fold (p<0.05).    
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At 2-weeks, the expression level of EGF was initially down-regulated in all PN, DN 
and RN but not in NegC (Fig.15A, p<0.05). After 12-weeks, EGF was significantly up-
regulated in PN and DN, where PN has about 3.2-fold and DN has about 2.5-fold greater 
than the control respectively (p<0.05). All groups had EGF level lower than the baseline 
level of the control (p>0.05).  
At 2-weeks post laceration, mRNA expression of AMPK-1 was up-regulated in all 
4 groups (Fig. 11). AMPK-1 expression levels at 12-weeks was down-regulated in all 
groups, except for PN where AMPK-1 remained higher than the control by 3.0-fold 
(p<0.05). RN had the highest AMPK-1 (4.50-fold, p<0.05) expression level. 
The gene expression level of PGC-1 (Fig 12A) was up-regulated in all 4 groups at 
2-weeks post-laceration compared against the control (p<0.05). Sirt-1 was down-regulated in 
PN and DN but the level was increased in RN and NegC. PN has 0.15-fold lower Sirt-1 level 
than the control (p<0.05). After 12-weeks, PGC-1 was down-regulated in all groups except 
for DN and RN. In DN, PGC-1 expression level remained higher than the control by 3.5-
fold, while RN has PGC-1 expression level of about 15.0-fold greater than the control 
(p<0.05). Sirt-1 was up-regulated to the baseline level of the control (p<0.05) with PN 
having the highest Sirt-1 expression level, about 3.5-fold greater than the control (p<0.05).  
 At 2-weeks (Fig.12B), CNTF was significantly down-regulated in all (p<0.05) 
where RN had the highest CNTF level (>0.55-fold). After 12-weeks, CNTF was up-
regulated in all groups except for RN. In PN and DN, CNTF in PN remained higher than the 















Figure 9   Fold changes (normalized to Lamin A) of  Follistatin, Decorin and HGF.  ANOVA 
and post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified 
homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats; P-values 
were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC).  
 
6.2.2.3- Correlations between markers   
In PN, the expression of collagen and aggrecan were decreased over 12-weeks to 
3.25-fold and 0.24-fold higher than control respectively. It has the lowest aggrecan and 
second lowest collagen expression level after 12-weeks. This was associated with an 
increase in AMPK-1a (2.96-fold, p<0.05), EGF (3.24-fold, p<0.05), Sirt1 (3.43-fold, 
p<0.05), CNTF (1.93-fold, p<0.05) and decorin (11.28-fold, p<0.05). A corresponding 
decrease in IGF1 (0.015-fold, p<0.05), TGFb2 (0.018-fold, p<0.05), galectin-1 (0.11-fold, 
p<0.05), vimentin (0.21-fold, p<0.05), R-spondin-1 (0.29-fold, p<0.05), CTGF and HGF 
(0.74-fold, p<0.05), and Shh (1.64-fold, p<0.05) is observed.  
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DN has the highest collagen and aggrecan levels at 15.76-fold and 7.69-fold more 
than the control respectively. This was associated with an increase in the expression of NT4 
(24.86-fold, p<0.05), myostatin (0.85-fold, p<0.05), CTGF (1.62-fold, p<0.05), TGFb2 
(0.21-fold, p<0.05), GDNF (17.78-fold, p<0.05), R-spondin-1 (0.46-fold, p<0.05), IGF1 
(0.15-fold, p<0.05) and HGF (0.55-fold, p<0.05). There was also a decrease AMPK-1a 
(0.48-fold, p<0.05), EGF (2.44-fold, p<0.05), CNTF (1.34-fold, p<0.05) and follistatin 
(8.13-fold, p<0.05) expression levels.   
RN has the lowest collagen (0.13-fold) and second lowest aggrecan (2.15-fold) levels 
compared to the control.  This corresponds to an increase in PGC-1a (14.99-fold, p<0.05), 
follistatin (1.38-fold, p<0.05), AMPK-1a (1.34-fold, p<0.05) and CNTF (0.48-fold, p<0.05). 
There is a decrease in CTGF (1.79-fold, p<0.05), R-spondin-1 (0.58-fold, p<0.05), Shh 
(6.61-fold, p<0.05), IGF1 (0.11-fold, p<0.05), HGF (1.73-fold, p<0.05) and myostatin (0.56-
fold, p<0.05) expression levels. 
Table 5A Correlation between collagen-1a and other selected fibrosis markers with respect 
to overall fold change in gene expression in all groups 
 
Gene PN DN  RN  NegC  r 
TGFb2 -0.24* -0.22
*,#
 -0.01 0.02 0.6407 
HGF -6.81* -1.78* 0.50
*,#
 -2.56* 0.3903 
GDNF -2.13 -27.68* -7.51 -7.00 0.7735 
Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 0.5246 










Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
 
Table 5B Correlation between aggrecan and other selected fibrosis markers with respect to 
overall fold change in gene expression in all groups 
 
Gene PN DN  RN  NegC  r 
TGFb2 -0.24* -0.22
*,#
 -0.01 0.02 0.43 
HGF -6.81* -1.78* 0.50
*,#





 0.15 -0.33 -0.4568 
IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* 0.6986 








Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 0.4969 
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Galectin-1 -0.43* -0.18 -0.05 -0.20 0.6324 
Collagen-1 -11.10 -9.45 -23.66 -8.50 0.7748 
Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
 
Table 5C Correlation between vimentin and other selected fibrosis markers with respect to 
overall fold change in gene expression in all groups 
 
Gene PN DN  RN  NegC  r 
TGFb2 -0.24* -0.22
*,#
 -0.01 0.02 0.5159 
HGF -6.81* -1.78* 0.50
*,#
 -2.56* 0.8024 
NT-4 -13.71 24.10
#








Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 0.5335 
Sirt-1 3.28* 0.92 -1.63 -2.03 -0.4739 
Galectin-1 -0.43* -0.18 -0.05 -0.20 0.6999 
Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
 
6.2.3- Atrophy markers 
Atrogin-1, MuRF-1, Complement-3  
The expression level of atrogin-1 and MuRF-1 were up-regulated in all 4 groups at 2-
weeks post-laceration compared with the control (p>0.05) (Fig. 10). After 12-weeks, 
atrogin-1 was down-regulated in all groups except for DN. In DN, atrogin-1 expression level 
remained higher than the control by 4.0-fold (p<0.05). On the other hand, MuRF-1 was 
down-regulated in RN PN and NegC, and up-regulated in DN.  In DN, MuRF-1 expression 
level remained higher than the control by 3.4-fold while in PN, the level is about 0.34-fold 
greater than the control (p<0.05). At 2-weeks, the expression level of complement-3, another 
atrophy marker which degrades fast (r = -0.3773) and slow myosin heavy chains (r = -
0.4383), was the highest for NegC (about 22-fold greater than the control, p<0.05).  At 2-
weeks post laceration, mRNA expression of complement-3 was up-regulated in all 4 groups, 
with the highest expression noted with NegC (Fig. 18B). After 12-weeks, complement-3 was 
down-regulated in all groups, but the expression level remained higher than the control 





            
Figure 10. Fold changes (normalized to Lamin A) of MuRF-1 and Atrogin-1. ANOVA and 
post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified the 
homogenous sub-sets that were not significantly different (See Appendix 4). P-values were 
calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically significant. (* 
- indicates significant difference (p<0.05) to Positive Control, PosC).  
6.2.3.1- Pro-atrophy markers  
Myostatin, Myogenin, AMPK-1 
At 2-weeks post laceration, mRNA expression of myostatin, and AMPK-1 were up-
regulated in all 4 groups (Fig. 11). After 12-weeks, myostatin was further up-regulated in 
all groups, except for PN, where it recorded a down-regulation. In DN, myostatin 
expression level further was up-regulated by 0.88-fold (p<0.05). AMPK-1 expression 
levels at 12-weeks was down-regulated in all groups, except for PN where AMPK-1 
remained higher than the control by 3.0-fold (p<0.05). RN had the highest AMPK-1 
(4.50-fold, p<0.05) expression level. The expression level of myogenin was significantly 
up-regulated in DN, RN and NegC at 2-weeks post-laceration compared against the 
control (p<0.05). In PN, the myogenin expression level was down-regulated but was not 
statistically significant (p>0.05).  After 12-weeks, myogenin expression level in RN and 






Figure 11. Fold changes (normalized to Lamin A) of Myostatin and AMPK-1. ANOVA 
and post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified the 
homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats (n=3); p-
values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC).  
 
6.2.3.2- Anti-atrophy markers  
Calpain-3, IGF1, PGC-1, Sirt1, NT4, GDNF, CNTF, Decorin, Follistatin 
At 2-weeks post laceration (Figure 12A), calpain-3 expression level was down-
regulated in all groups except for PN. PN has the highest calpain-3 expression level. In PN 
the expression level was about 2.0-fold greater than the control (p<0.05).  IGF-1 expression 
levels were upregulated in all groups, except in NegC (P<0.05). After 12-weeks, IGF-1 was 
down-regulated back to the control levels. Calpain-3 was noted to be further down-regulated 
in all groups, except in RN where it was up-regulated compared to the control (p<0.05).  
The gene expression level of PGC-1 (Fig 12A) was up-regulated in all 4 groups at 
2-weeks post-laceration compared against the control (p<0.05). Sirt-1 was down-regulated in 
PN and DN but the level was increased in RN and NegC. PN has 0.15-fold lower Sirt-1 level 
than the control (p<0.05). After 12-weeks, PGC-1 was down-regulated in all groups except 
for DN and RN. In DN, PGC-1 expression level remained higher than the control by 3.5-
fold, while RN has PGC-1 expression level of about 15.0-fold greater than the control 
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(p<0.05). Sirt-1 was up-regulated to the baseline level of the control (p<0.05) with PN 












Figure 12A.   Fold changes (normalized to Lamin A) of Calpain-3, IGF-1, PGC-1 and Sirt-
1. ANOVA and post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified 
the homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats; p-values 
were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC). 
 
At 2-weeks (Fig. 12B), NT-4 was up-regulated in all groups except for NegC (p>0.05), 
with PN having the highest NT-4 level (> 14.0-fold). Similarly, GDNF was up-regulated in 
all groups (p<0.05) with DN having the highest GDNF expression level (>45-fold, p<0.05). 
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Conversely, except for RN, CNTF was significantly down-regulated in all (p<0.05) where 
RN had the highest CNTF level (>0.55-fold). Decorin and follistatin which are also anti-
fibrosis markers were shown in the previous section to be upregulated in all groups at 2-
weeks. 
After 12-weeks, NT-4 was down-regulated in all groups except for DN. (Figure 9.) In 
DN, NT-4 expression levels remained higher than the control (22.0-fold, p<0.05). Except for 
DN, GDNF was down-regulated in all other groups. In DN, GDNF expression level 
remained high (> 20.0-fold, p>0.05). CNTF was up-regulated in all groups except for RN. In 
PN and DN, CNTF in PN remained higher than the control by 1.93-fold in PN and that in 









Figure 12B.   Fold changes (normalized to Lamin A) of NT-4, GDNF, CNTF.  ANOVA and 
post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified the 
homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats (n=3); p-
values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC). 
6.2.3.3- Correlations between markers  
In PN, the expression of atrogin-1, MuRF1 and complement-3 were decreased to 
0.32-fold, 0.36-fold and 1.83-fold lower than the control respectively. It has the lowest 
atrogin-1, MuRF1 and complement-3 expression levels after 12-weeks. This was associated 
with an increase in Sirt1 (3.43-fold, p<0.05), CNTF (1.93-fold, p<0.05) and decorin (11.28-
fold, p<0.05). A corresponding decrease in pro-atrophy factors AMPK-1a (2.96-fold, 
p<0.05), and anti-atrophy factors calpain-3 (0.45-fold, p<0.05), IGF1 (0.015-fold, p<0.05) is 
observed.  
The expression of atrogin-1, MuRF-1 and complement-3 in DN were increased to 
3.76-fold, 3.44-fold and 6.66-fold higher than the control respectively over 12-weeks.  
DN has the highest atrogin-1, MuRF1 and second highest complement-3 expression levels 
after 12-weeks. This was associated with an increase in myostatin (0.85-fold, p<0.05), 
CNTF (1.34-fold, p<0.05) and NT4 (24.86-fold, p<0.05). A corresponding decrease in 
AMPK-1a (0.48-fold, p<0.05), IGF1 (0.15-fold, p<0.05), GDNF (17.78-fold, p<0.05) and 
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follistatin (8.13-fold, p<0.05) is observed. 
In RN, the expression of atrogin, MuRF1 and complement-3 was decreased over 12-
weeks to 0.87-fold, 1.27-fold and 8.41-fold higher than control respectively. It has the 
highest complement-3 expression level after 12-weeks, while its atrogin-1 and MuRF1 
levels are intermediate between PN and DN. This was associated with an increase in calpain-
3 (0.94-fold, p<0.05), PGC-1a (14.99-fold, p<0.05) and myostatin (0.56-fold, p<0.05). 
A corresponding decrease in IGF1 (0.19-fold, p<0.05), CNTF (0.48-fold, p<0.05), follistatin 
(1.38-fold, p<0.05), AMPK-1a (1.34-fold, p<0.05) and myogenin (3.54-fold, p<0.05) is 
observed. 
Table 6A Correlation between atrogin-1 and other selected atrophy markers with respect to 
overall fold change in gene expression in all groups 
 













Calpain-3 -1.49* -0.13 0.65
#








Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
Table 6B Correlation between MuRF-1 and other selected atrophy markers with respect to 
overall fold change in gene expression in all groups 
 







 -1.17* 0.9471 





Calpain-3 -1.49* -0.13 0.65
#








Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
Table 6C Correlation between complement-3 and other selected atrophy markers with 
respect to overall fold change in gene expression in all groups  
 






















Calpain-3 -1.49* -0.13 0.65
#
 0.37 -0.5803 
PGC-1a -1.48 2.24 9.64
#
 -2.35 -0.4472 




6.2.4- Myogenesis markers  
MyoD, Myogenin, Mef2, Desmin 
 
The expression level of myoD (Fig. 13) was down-regulated in PN and DN at 2-
weeks post-laceration (p<0.05) with the lowest expression level (0.55-fold lower than the 
level of the control). After 12-weeks, myoD was up-regulated in all groups, where DN had 
the highest myoD level (p<0.05). The expression level of myogenin was significantly up-
regulated in DN, RN and NegC at 2-weeks post-laceration compared against the control 
(p<0.05). In PN, the myogenin expression level was down-regulated but was not statistically 
significant (p>0.05).  After 12-weeks, myogenin expression level in RN and NegC remained 
higher than the control (p<0.05) except for PN (1.60-fold less than the control, p>0.05). 
At 2-weeks, Mef-2 expression level normalized to lamin A  (Fig 13) was down-
regulated in all groups except for NegC (p<0.05). PN has the lowest Mef-2 expression 
level (about 0.75-fold lower than the control).  NegC has the highest Mef-2 expression 
level (about 2.92-fold higher than the control, p<0.05). After 12-weeks, Mef-2 A was up-
regulated in all groups with DN having the highest expression level (about 3.15-fold, 








Figure 13. Fold changes (normalized to Lamin A) of myoD, myogenin, Mef-2and desmin. 
ANOVA and post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified 
the homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats (n=3); p-
values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC).  
 
The mRNA expression levels of the intermediate filaments desmin, vimentin and 
nestin (Fig. 13) were significantly up-regulated in all groups at 2-weeks post-laceration 
compared against the control. In PN, the desmin, vimentin and nestin expression level 
was about 0.26-fold, 3.0-fold and 3.0-fold greater than the control, respectively (p<0.05).  
After 12-weeks, desmin in all groups remained higher than the control (p<0.05), where in 
PN it was about 0.11-fold greater than the control (p<0.05). Conversely, vimentin and 
nestin was down-regulated in PN, DN and NegC, but not in DN where the expression 
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were >2.0-fold greater than the control (p<0.05).  
         
Figure 14A. Western blot analysis of Myogenin and myoD at 2-weeks (white) and 12-weeks 
(black) post-repair (with alpha tubulin as the loading control). P-values were calculated by 
Scheffe’s post-hoc test, where p<0.05 is considered statistically significant. The optical 
densitometry (OD) quantification of the protein expression level normalized to alpha 
tubulin, using GelPro v4.5 (arbitrary units).  
 
Immunoblotting results (Fig. 14A) showed that myoD protein expression level was 
significantly down-regulated in PN and DN at 2-weeks post-laceration but not in RN, 
compared against the control (p>0.05). After 12-weeks, myoD was up-regulated in PN, 
DN and RN (p<0.05). The highest mean level of myoD were in PN and DN at 12-weeks 
post-laceration compared with other subgroups (p<0.05). Myogenin was significantly 
down-regulated in DN and RN at 2-weeks post-laceration (p<0.05). After 12-weeks, 
myogenin was down-regulated in DN (p<0.05). The highest mean level of myogenin 
were present in PN and RN at 12-weeks post-laceration compared with the control 
(p<0.05). The highest mean level of myogenin were present in PN and RN at 12-weeks 
post-laceration compared with the control (p<0.05). Immunoblotting results for desmin 
and vimentin (Fig. 14B) showed significantly up-regulation in all groups at 2-weeks post-
laceration compared to the control (p<0.05). After 12-weeks, desmin expression level in 
61 
 
all groups returned to the baseline level of the control (p<0.05). Vimentin was also down-
regulated in PN, RN and NegC, but not in DN, where it remained highly expressed 
(p<0.05). The highest mean level of desmin and vimentin was present in PN at 2-weeks 
post-laceration compared with the control (p<0.05). 
              
 
Figure 14B. Western blot analysis of Vimentin and Desmin at 2-weeks (white) and 12-
weeks (black) post-repair (with alpha tubulin as the loading control). P-values were 
calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically significant. 
The optical densitometry (OD) quantification of the protein expression level was normalized 
to alpha tubulin, using GelPro v4.5 (arbitrary units).  
  
6.2.4.1- Pro-myogenesis markers  
Galectin-1, Decorin, Follistatin, IGF1, HGF, EGF, Shh, NT4, GDNF, CNTF, PGC-1, 
Sirt1, R-spondin-1 
Of the pro-myogenesis markers, galectin-1 (Figs. 8A and B) is a pro-fibrosis marker, 
while decorin and follistatin (Fig. 9) are anti-fibrosis markers. AMPK-1 (Fig 11) is also a 
pro-atrophy and anti-fibrosis marker, while IGF-1, PGC-1, Sirt-1, NT4 GDNF and CNTF 
(Figs. 12A and 12B) are anti-atrophy markers. NT-4, GDNF and CNTF are also pro-axonal 
regeneration factors. NT4, GDNF and Sonic hedgehog also have pro-fibrosis actions. All 
these have been shown above.   
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 The expression level of HGF and IGF-1 (as shown before) were significantly up-
regulated in all groups while EGF was initially down-regulated in all PN, RN and DN, but 
not in NegC, at 2-weeks post-laceration (Fig. 15A, p<0.05). NegC had the highest IGF-1 
expression level (>4-fold greater than control) while PN had the highest IGF-1 expression 











Figure 15A.   Fold changes (normalized to Lamin A) of HGF, EGF and IGF. ANOVA and 
post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified the 
homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats; p-values 
were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 




After 12-weeks, IGF-1 was down-regulated to the baseline level while HGF was 
down-regulated, but remained higher than the baseline level of the control in all groups 
(p<0.05). EGF was significantly up-regulated in PN and DN, where PN has about 3.2-fold 
and DN has about 2.5-fold greater than the control respectively (p<0.05). RN has the highest 
level of HGF (>1.7-fold) while all other groups had EGF level lower than the baseline level 
of the control (p>0.05).             
 Immunoblotting of R-spondin-1 which is also a pro-fibrosis marker was previously 
shown (Fig 8C). 
6.2.4.2- Anti-myogenesis markers  
Myostatin, TGF2, CTGF, AMPK-1 
 
At 2-weeks post laceration, myostatin (Fig. 15B) was up-regulated in all 4 groups. 
TGF2, a pro-fibrosis marker was only up-regulated for PN and DN. After 12-weeks, 
myostatin was further up-regulated in all groups except for PN. In DN, myostatin 
expression level remained higher than the control by 0.88-fold (p<0.05). On the other 
hand, TGF2 was down regulated to baseline values, in all but DN.  AMPK-1a (Fig 11) 







Figure 15B.   Fold changes (normalized to Lamin A) of Myostatin, TGF2. ANOVA and 
post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified the 
homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats; p-values 
were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC). 
 
6.2.4.3- Correlations between markers 
In PN, the expression of myoD was increased over 12-weeks to 2.45-fold higher than 
control. It has the lowest myogenin expression level after 12-weeks at 1.66-fold compared to 
the control. This was associated with an decrease in TGFb2 (0.018-fold, p<0.05) and CTGF 
(0.74-fold, p<0.05), galectin-1 (0.11-fold, p<0.05), IGF1(0.015-fold, p<0.05), HGF (0.74-
fold, p<0.05), R-spondin-1 (0.29-fold, p<0.05), Shh (1.64-fold, p<0.05). A corresponding 
increase in AMPK-1a (2.96-fold, p<0.05), decorin (11.28-fold, p<0.05), EGF (3.24-fold, 
p<0.05), CNTF (1.93-fold, p<0.05) and Sirt1 (3.43-fold, p<0.05) is noted.   
In DN, the expression of myoD and myogenin were decreased over 12-weeks to 
4.49-fold and 10.81-fold higher than control respectively. This was associated with an 
decrease in TGFb2 (0.22-fold, p<0.05) and AMPK-1a (0.48-fold, p<0.05), follistatin (8.13-
fold, p<0.05), IGF1 (0.15-fold, p<0.05), HGF (0.55-fold, p<0.05), GDNF (17.78-fold, 
p<0.05) and R-spondin-1 (0.46-fold, p<0.05). A corresponding increase in myostatin (0.85-
fold, p<0.05), CTGF (1.62-fold, p<0.05), EGF (2.44-fold, p<0.05), NT4 (24.86-fold, 
p<0.05) and CNTF (1.34-fold, p<0.05) was found. 
In RN, the expression of myoD was increased over 12-weeks to 2.48-fold higher 
than control, while the myogenin level was decreased to 3.54-fold greater than control.  
This was associated with a decrease in AMPK-1a (1.34-fold, p<0.05) and CTGF (1.79-fold, 
p<0.05), follistatin (1.38-fold, p<0.05), IGF1 (0.11-fold, p<0.05), CNTF (0.48-fold, p<0.05), 
and R-spondin-1 (0.58-fold, p<0.05). A corresponding increase in myostatin (0.56-fold, 
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p<0.05), HGF (1.73-fold, p<0.05), Shh (6.61-fold, p<0.05) and PGC-1a (14.99-fold, p<0.05) 
is seen.  
Table 7A Correlation between myoD and other selected myogenesis markers with respect to 
overall fold change in gene expression in all groups  
 
Gene PN DN  RN  NegC  r 
TGFb2 -0.24* -0.22
*,#












 0.15 -0.33 0.4899 
IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* 0.3864 
NT-4 -13.71 24.10
#








Mef-2a 0.28 1.58 0.01 -0.55 0.3788 
Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
Table 7B Correlation between myogenin and other selected myogenesis markers with 
respect to overall fold change in gene expression in all groups 
 
Gene PN DN  RN  NegC  r 
Follistatin -3.15 -10.32
*,#





 0.15 -0.33 -0.3928 
IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* 0.5418 








Mef-2a 0.28 1.58 0.01 -0.55 0.633 
Desmin 0.02 -0.15
*








Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
6.2.5- Isometric contraction markers  
 Slow troponin-I, fast troponin-I, slow myosin heavy chain, fast myosin heavy chain, 
embryonic myosin heavy chain  
Quantitative analysis of genes related to isometric contraction including myosin 
heavy chain -3 (embryonic), -7 (slow) and -4 (Fast); and slow troponin-I and fast troponin-I, 
were assessed for their expression levels in lacerated medial gastrocnemius of SD rat after 2-
weeks and 12-weeks post-surgery, normalised to lamin A (Fig. 16A). This is done to 
investigate the functional recovery status of the lacerated skeletal muscle in different 
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treatment groups with respect to the genes involved in synthesis of contractile proteins at the 
molecular level. The electrophysiologic study about the functional recovery of the lacerated 
skeletal muscle is done in another project. 
The slow troponin-1 and fast troponin-1 expression levels were up-regulated in all 
groups at 2-weeks post-laceration compared against the control, but were not significantly 
different from the control (p=0.07). After 12-weeks, both slow troponin-1 and fast troponin-
1 were down-regulated to the baseline level of the control in all groups except for DN where 
the slow troponin-1 expression level was 4.5-fold higher than the control and for RN where 
has the highest expression level was for fast troponin-I, more than 12-fold greater than the 
control (p<0.05). 
The expression level of embryonic myosin heavy chain was significantly up-
regulated in PN and NegC at 2-weeks post-laceration compared against the control (p<0.05). 
In DN and RN, the embryonic myosin heavy chain expression level are also up-regulated 
but are not statistically significant (p>0.05).  After 12-weeks, embryonic myosin heavy chain 
was significantly down-regulated in PN and DN, where DN has about 29.2-fold and RN has 
about 17.3-fold greater than the control respectively (p<0.05). All other groups have 
embryonic myosin heavy chain level higher than the baseline level of the control but are not 
statistically significant (p>0.05).  
The expression level of slow myosin heavy chain was significantly down-regulated 
in NegC at 2-weeks post-laceration compared against the control (p<0.05). In other groups, 
the slow myosin heavy chain expression levels are also down-regulated but are not 
statistically significant (p>0.05).  After 12-weeks, slow myosin heavy chain expression level 
in all groups remained lower than the control except for DN, where DN has about 0.45-fold 
greater than the other groups (p<0.05).  
Immunoblotting results (Fig. 16B) showed that slow myosin heavy chain was 
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significantly up-regulated in PN and DN at 2-weeks post-laceration but not in RN, compared 
against the control (p>0.05). After 12-weeks, slow myosin heavy chain was down-regulated 
to the baseline level of the control (p>0.05). The data showed that the highest mean level of 
slow myosin heavy chain were present in PN and DN at 2-weeks post-laceration compared 

















Figure 16A.   Fold changes (normalized to Lamin A) of Slow Troponin-I, Fast Troponin-I, 
Embryonic Myosin Heavy Chain (MHC-embryonic), Slow Myosin Heavy Chain (MHC-
slow) and Fast Myosin heavy Chain (MHC fast).  ANOVA and post-hoc tests at 2-weeks 
(white) and 12-weeks (black) post-repair identified the homogenous sub-sets that were not 
significantly different (See Appendix 4). Data is expressed as means ± SD of three 
independent experiments obtained with 3 rats. P-values were calculated by Scheffe’s post-
hoc test, where p<0.05 is considered statistically significant. (* - indicates significant 
difference (p<0.05) to Positive Control, PosC). 
 
The expression level of fast myosin heavy chain was significantly down-regulated in 
PN, RN and NegC at 2-weeks post-laceration compared against the control (p<0.05). PN has 
about 0.35-fold, RN has 0.85-fold and NegC has about 0.55-fold lower than the control. In 
DN, the fast myosin heavy chain expression level is also down-regulated but is not 
statistically significant (p>0.05).  After 12-weeks, fast myosin heavy chain expression level 
in all groups increased to the baseline level of the control except for DN. DN has about 0.04-






Figure 16B.   Optical densitometry quantification of slow (Type 1) and fast (Type 2B) 
myosin heavy chain protein expression levels normalized to alpha tubulin, using GelPro v4.5 
(arbitrary units). Data was obtained from three independent experiments with 3 rats. p-
values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. Non-significant homogenous sub-groups are noted.  (* - indicates significant 
difference (p<0.05) to Positive Control, CSham). 
 
Immunoblotting results also showed that fast myosin heavy chain was significantly 
down-regulated in PN, DN and RN at 2-weeks post-laceration compared against the control 
(p<0.05). After 12-weeks, fast myosin heavy chain was further down-regulated to lower than 
the control (p<0.05). The highest mean level of fast myosin heavy chain was present in RN 
at 2-weeks post-laceration compared with other subgroups (p<0.05).  
6.2.5.1- Pro-Slow myosin heavy chain and Slow Troponin-I markers, Anti-Fast myosin 
heavy chain and Fast Troponin-I markers 
Myogenin, PGC-1a, Sirt1, Shh, NT4, CNTF, Mef2a, myostatin 
6.2.5.2- Anti-Slow myosin heavy chain and Slow Troponin-I markers, Pro-Fast myosin 
heavy chain and Fast Troponin-I markers 
myoD, IGF1, CNTF 
 Of the myosin heavy chain isoform regulators for myosin heavy chain proteins, 
myoD (for fast MHC) and myogenin (for slow MHC) are also myogenesis markers (Figs 13 
and 14B); NT4 (for slow MHC), CNTF (for fast MHC) and IGF-1 (for embryonic MHC) are 
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also anti-atrophy markers as well as pro-re-innervation markers (Figs. 12A and 12B). PGC-
1a and Sirt-1 (for slow MHC) are also anti-atrophy (Fig. 12A) as well as mitochondrial 






Figure 17.  Fold changes (normalized to Lamin A) of myogenin, PGC-1a, NT4, Sonic 
Hedgehog, Sirt1 and AMPK-1a.  ANOVA and post-hoc tests at 2-weeks (white) and 12-
weeks (black) post-repair identified the homogenous sub-sets that were not significantly 
different (See Appendix 4). Data is expressed as means ± SD of three independent 
experiments obtained with 3 rats. P-values were calculated by Scheffe’s post-hoc test, where 
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p<0.05 is considered statistically significant. (* - indicates significant difference (p<0.05) to 
Positive Control, PosC).  
6.2.5.3- Anti-fast and anti-slow myosin heavy chain, and anti-fast and slow troponin-I 
markers, TGFb2, atrogin-1, MuRF-1, complement-3  
 TGFb2 is described in section 6.2.2.1 (Fig 8A), while atrogin-1 and MuRF-1 are 
described in section 6.2.3 (Fig10), complement-3 in section 6.2.3 (Fig18B). 
 
6.2.5.4- Correlations between markers  
In PN, the expression of embryonic myosin heavy chain was decreased over 12-
weeks to 12.83-fold higher than control. This was associated with an increase in CNTF 
(1.93-fold, p<0.05), and a decrease in HGF (0.74-fold, p<0.05), Shh (1.64-fold, p<0.05) and 
IGF1 (0.015-fold, p<0.05). The expression of fast myosin heavy chain (1.13-fold) was 
increased but the fast troponin-I (0.45-fold) was reduced over 12-weeks. It has the highest 
fast myosin heavy chain expression level after 12-weeks. This was associated with an 
increase in Sirt1 (3.43-fold, p<0.05), MuRF1 (0.36-fold, p<0.05) and CNTF (1.93-fold, 
p<0.05). A decrease in atrogin-1 (0.32-fold, p<0.05), Shh (1.64-fold, p<0.05) and TGFb2 
(0.018-fold, p<0.05) is observed.  The expression of slow myosin heavy chain (0.22-fold) 
was increased but the slow troponin-I (0.042-fold) was decreased over 12-weeks. It has the 
lowest slow troponin-I expression level after 12-weeks. This was associated with an increase 
in Sirt1 (3.43-fold, p<0.05), MuRF1 (0.36-fold, p<0.05), CNTF (1.93-fold, p<0.05), and 
decrease in atrogin-1 (0.32-fold, p<0.05), IGF1( 0.015-fold, p<0.05), TGFb2 (0.018-fold, 
p<0.05), Shh (1.64-fold, p<0.05).   
In DN, the expression of embryonic myosin heavy chain was decreased over 12-
weeks to 29.44-fold higher than control. It has the highest embryonic myosin heavy chain 
expression level after 12-weeks. This was associated with an increase in CNTF (1.34-fold, 
p<0.05). A corresponding decrease in follistatin (8.13-fold, p<0.05), HGF (0.55-fold, 
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p<0.05), GDNF (17.78-fold, p<0.05), and IGF1 (0.15-fold, p<0.05) is observed. 
The expression of fast myosin heavy chain (1.13-fold) and fast troponin-I (0.45-fold) were 
decreased over 12-weeks. It has the lowest fast myosin heavy chain and fast troponin-I 
expression levels after 12-weeks. This was associated with an increase in atrogin-1 (3.76-
fold, p<0.05), MuRF1 (3.44-fold, p<0.05), myostatin (0.85-fold, p<0.05), NT4 (24.86-fold, 
p<0.05), CNTF (1.34-fold, p<0.05), myoD (4.49-fold, p<0.05), and a decrease in 
complement-3 (6.66-fold, p<0.05) and TGFb2 (0.21-fold, p<0.05). The expression of slow 
myosin heavy chain (0.22-fold) and slow troponin-I (0.042-fold) were increased over 12-
weeks. It has the highest slow myosin heavy chain and slow troponin-I expression level after 
12-weeks. This was associated with an increase in atrogin-1 (3.76-fold, p<0.05), MuRF1 
(3.44-fold, p<0.05), myostatin (0.85-fold, p<0.05), NT4 (24.86-fold, p<0.05),  CNTF (1.34-
fold, p<0.05), myoD (4.49-fold, p<0.05), and a decrease in complement-3 (6.66-fold, 
p<0.05), IGF1 (0.15-fold, p<0.05), TGFb2 (0.21-fold, p<0.05). 
In RN, the expression of embryonic myosin heavy chain was decreased over 12-
weeks to 3.37-fold higher than control. It has the lowest embryonic myosin heavy chain 
expression level after 12-weeks. This was associated with an increase in HGF (1.73-fold, 
p<0.05) and Shh (6.60-fold, p<0.05). A corresponding decrease in myogenin (3.54-fold, 
p<0.05), CNTF (0.48-fold, p<0.05), follistatin (1.38-fold, p<0.05), IGF1 (0.10-fold, p<0.05) 
is observed. The expression of fast myosin heavy chain (1.12-fold) was increased but fast 
troponin-I (1.63-fold) was decreased over 12-weeks. It has the highest fast troponin-I 
expression level after 12-weeks. This was associated with an increase in Shh (6.60-fold, 
p<0.05), and a decrease in TGFb2 (0.022-fold, p<0.05), atrogin-1 (0.87-fold, p<0.05), 
MuRF1 (1.27-fold, p<0.05), myogenin (3.54-fold, p<0.05), myostatin (0.56-fold, p<0.05), 
complement-3 (8.41-fold, p<0.05), CNTF (0.48-fold, p<0.05). The expression of slow 
myosin heavy chain (0.22-fold) and slow troponin-I (0.042-fold) were decreased over 12-
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weeks. This was associated with an increase in PGC-1a (14.99-fold, p<0.05), Shh (6.60-fold, 
p<0.05), myostatin (0.56-fold, p<0.05), and a decrease in CNTF (0.48-fold, p<0.05), 
atrogin-1 (0.87-fold, p<0.05), MuRF1 (1.27-fold, p<0.05), myogenin (3.54-fold, p<0.05), 
complement-3 (8.41-fold, p<0.05). 
Table 8A Correlation between fast myosin heavy chain and other selected fiber 
transformation markers with respect to overall fold change in gene expression in all groups 
 






















 -0.01 0.02 -0.6738 
NT-4 -13.71 24.10
#








Sonic Hedgehog -6.68* -2.62 0.95
#
















Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
Table 8B Correlation between slow myosin heavy chain and other selected fiber 
transformation markers with respect to overall fold change in gene expression in all groups 
 






















 -0.01 0.02 -0.3466 
IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* -0.3741 
NT-4 -13.71 24.10
#








Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 0.4912 
PGC-1a -1.48 2.24 9.64
#








Mef-2a 0.28 1.58 0.01 -0.55 0.4309 














Table 8C Correlation between embryonic myosin heavy chain and other selected fiber 
transformation markers with respect to overall fold change in gene expression in all groups 
 
Gene PN DN  RN  NegC  r 







 -5.46* -3.00 0.501 
HGF -6.81* -1.78* 0.50
*,#
 -2.56* 0.535 
IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* 0.8378 








Sonic Hedgehog -6.68* -2.62 0.95
#








Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
Table 8D Correlation between fast troponin-I and other selected fiber transformation 
markers with respect to overall fold change in gene expression in all groups  
 
 
Gene PN DN  RN  NegC  r 
Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 0.4169 
Sirt-1 3.28* 0.92 -1.63 -2.03 0.388 
Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
 
Table 8E Correlation between slow troponin-I and other selected fiber transformation 
markers with respect to overall fold change in gene expression in all groups  
 
Gene PN DN  RN  NegC  r 







 12.43 -0.18 0.7736 
myoD 1.91 3.46
#
 0.75 0.30 0.8113 








Note: * p<0.05 at 2-weeks, # p<0.05 at 12-weeks 
 
 
6.2.6- Intra-Muscular Nerve Regeneration marker, GAP43  
The expression level of GAP-43 and HN-1 (Fig. 18) were up-regulated in all 4 
groups at 2-weeks post-laceration compared against the control (p>0.05). NegC has the 






Figure 18A.   Fold change (normalized to Lamin A) of GAP43 and HN-1.  ANOVA and 
post-hoc tests at 2-weeks (white) and 12-weeks (black) post-repair identified the 
homogenous sub-sets that were not significantly different (See Appendix 4). Data is 
expressed as means ± SD of three independent experiments obtained with 3 rats (n=3); p-
values were calculated by Scheffe’s post-hoc test, where p<0.05 is considered statistically 
significant. (* - indicates significant difference (p<0.05) to Positive Control, PosC). 
 
After 12-weeks, GAP-43 was down-regulate in all groups, but the expression 
level remained higher than the control (p>0.05).   
6.2.6.1- Pro-axonal regeneration markers 
NT4, GDNF, CNTF, IGF1, HGF, EGF, Galectin-1, Decorin, HN1, Follistatin, Shh 
The pro-axonal regeneration markers were grouped into the classical and non-
classical neurotrophic factors. The classical neurotrophic factors including NT4, GDNF, 
CNTF are also anti-atrophy markers, pro-myogenesis markers, as well as myosin heavy 
chain isoform regulators (Fig. 12B), while the non-classical neurotrophic markers have 
multiple functions either as anti-fibrosis markers (decorin and follistatin, Fig. 9; EGF Fig 
8A), anti-atrophy markers (decorin, follistatin, IGF-1 Fig 12A), pro-myogenesis markers 
(decorin, follistatin, galectin-1, HGF, IGF-1, Fig 15A) or pro-fibrosis markers (galectin-1, 
Figs 8A and 8B; Sonic hedgehog Fig 17). All have been demonstrated earlier.  
The expression level of HN1 (Fig. 18) was up-regulated in all 4 groups at 2-weeks 
post-laceration compared against the control (p>0.05). NegC has the highest HN1 
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expression level (5.5-fold, greater than the level of the control). After 12-weeks, the HN1 
expression in all groups remained higher than the control (p>0.05). Interestingly, 
histology did not show the presence of any nerve sprouts in PN, DN, RN and NegC. 
6.2.6.2- Anti-axonal regeneration markers  
Collagen-1, Aggrecan, TGF2, Complement-3, CTGF 
The anti-axonal regeneration markers were pro-fibrosis markers as demonstrated 
earlier (Fig 7A – collagen-1 and aggregan, Fig 8A for TGF2 and Fig 8B for CTGF). 
Complement-3 is an anti-axonal regeneration marker because it destroys newly regenerating 
axons (Fig.18B). 
 
                                     
Figure 18B. Fold change (normalized to Lamin A) of Complement-3. ANOVA and post-hoc 
tests at 2-weeks (white) and 12-weeks (black) post-repair identified the homogenous sub-
sets that were not significantly different (See Appendix 4). Data is expressed as means ± SD 
of three independent experiments obtained with 3 rats (n=3); p-values were calculated by 
Scheffe’s post-hoc test, where p<0.05 is considered statistically significant. (* - indicates 
significant difference (p<0.05) to Positive Control, PosC).  
 
6.2.6.3- Correlations between markers  
In PN, the expression of GAP43 was 0.85-fold higher than control. It has the highest 
GAP43 expression level after 12-weeks. This was associated with an increase in pro-axonal 
regeneration factors EGF (3.24-fold, p<0.05), decorin (11.28-fold, p<0.05), CNTF (1.93-
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fold, p<0.05) and HN1 (0.53-fold, p>0.05) expression respectively. A corresponding 
decrease in TGFb2 (0.018-fold, p<0.05), aggrecan (0.24-fold, p<0.05), IGF1 (0.015-fold, 
p<0.05), HGF (0.74-fold, p<0.05), galectin-1 (0.11-fold, p<0.05) and Shh (1.64-fold, 
p<0.05) was observed.   
In DN, the expression of GAP43 was decreased over 12-weeks to 0.59-fold higher 
than control. It has the lowest GAP43 expression level after 12-weeks. This was associated 
with an increase in pro-axonal regeneration factors EGF (2.44-fold, p<0.05), NT4 (24.86-
fold, p<0.05) and CNTF (1.34-fold, p<0.05), CTGF (1.62-fold, p<0.05). A corresponding 
decrease in TGFb2 (0.21-fold, p<0.05), complement-3 (6.66-fold, p<0.05), aggrecan (7.69-
fold, p<0.05), IGF1 (0.15-fold, p<0.05), HGF (0.55-fold, p<0.05), GDNF (17.78-fold, 
p<0.05) and follistatin (8.13-fold, p<0.05) is seen.  
In RN, the expression of GAP43 was decreased over 12-weeks to 0.82-fold higher 
than control.  This was associated with an increase in pro-axonal regeneration factors HGF 
(1.73-fold, p<0.05), Shh (6.61-fold, p<0.05), and increase in CTGF (1.79-fold, p<0.05) and 
PGC-1a (14.99-fold, p<0.05). A corresponding decrease in complement-3 (8.41-fold, 
p<0.05), aggrecan (2.15-fold, p<0.05), IGF1 (0.11-fold, p<0.05), CNTF (0.48-fold, p<0.05), 
follistatin (1.38-fold, p<0.05) is observed. 
Table 9 Correlation between GAP43 and other selected intr-muscular nerve regeneration 
markers with respect to overall fold change in gene expression in all groups  
 
Gene PN DN  RN  NegC  r 
Follistatin -3.15 -10.32
*,#
 -5.46* -3.00 0.3563 
HGF -6.81* -1.78* 0.50
*,#
 -2.56* 0.4788 
IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* 0.6643 
GDNF -2.13 -27.68* -7.51 -7.00 0.4441 
Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 0.6429 
Galectin-1 -0.43* -0.18 -0.05 -0.20 0.6718 
HN-1 0.26 -0.21 0.20 -0.11 0.4349 




6.2.7- Signaling Pathway Markers: 
(a) MAPK kinase pathway: p38, Erk1, Erk2 
(b) SMAD pathway: SMAD2, SMAD3 
 
Optical densitometry quantification showed that the highest mean level of phospho-
p38 were present in PN at 2-weeks post-laceration compared with the control (p<0.05). Both 
p38 and phospho-p38 protein expression level normalized to total p38 (Fig. 21) showed that 
the highest mean level of phospho-p38 were present in RN at 2-weeks post-laceration 
compared with the control (p<0.05). Immunoblotting results also showed that Erk1,2 and 
phospho-Erk1,2 (Fig 19) and SMAD2, 3 and phospho- SMAD2, 3 (Fig. 20) were 
significantly up-regulated in all groups at 2-weeks post-laceration compared against the 
control (p<0.05). After 12-weeks, Erk1,2 and phospho-Erk1,2 together with SMAD2, 3 and 
phospho- SMAD2,3 expression level in all groups remained higher than the control 
(p<0.05).  
Optical densitometry quantification of Erk1,2 and phospho-Erk1,2 protein expression 
level normalized to alpha tubulin (Fig 19) showed that the highest mean level of phospho-
Erk1,2 were present in DN at 2-weeks post-laceration compared with the control (p<0.05). 
The highest mean level of phospho-SMAD2 was present in DN at 12-weeks post-laceration 
compared with the control (p<0.05) while the highest mean level of phospho-SMAD3 was 







Figure 19. Western blot analysis of  p38, phospho-p38, Erk-1, Erk-2 and phospho-Erk-1 and 
Erk-2 (with alpha tubulin as the loading control). Optical densitometry quantification was 
obtained from three independent experiments with 3 rats at 2 time points (white bars - 
2weeks; black bars – 12weeks). P-values were calculated by Scheffe’s post-hoc test, where 
p<0.05 is considered statistically significant. (* - indicates significant difference (p<0.05) to 
Positive Control, PosC). 
 
 
Erk1,2 and phospho-Erk1,2 protein expression level normalized to total Erk1 and 2 
(Fig 21) showed that the highest mean level of phospho-Erk1,2 were present in PN at 2-
weeks post-laceration compared with the control (p<0.05). For SMAD2, 3 and phospho-
SMAD2,3 protein expression level normalized to total SMAD2 and 3 (Fig. 21), the highest 
mean level of phospho-SMAD2 was present in DN at 2-weeks post-laceration compared 
with the control (p<0.05). The highest mean level of phospho-SMAD3 was present in PN at 






Figure 20. Western blot analysis of SMAD2, SMAD3, phospho-SMAD2 and phospho- 
SMAD3 (with alpha tubulin as the loading control). Optical densitometry quantification was 
obtained from three independent experiments with 3 rats at 2 time points (white bars - 
2weeks; black bars – 12weeks). P-values were calculated by Scheffe’s post-hoc test, where 
p<0.05 is considered statistically significant. (* - indicates significant difference (p<0.05) to 







Figure 21. Western blot analysis of phospho-p38 relative to total p38, phospho-Erk1 and 
phospho-Erk2 relative to total Erk, phospho-SMAD2 and phospho-SMAD3 relative to total 
SMAD2/3 (with alpha tubulin as the loading control). Optical densitometry quantification 
was obtained from three independent experiments with 3 rats at 2 time points (white bars - 
2weeks; black bars – 12weeks). P-values were calculated by Scheffe’s post-hoc test, where 







We demonstrated that the temporal gene expression of various neurotrophic factors, 
anti-atrophic factors and pro-fibrotic factors at 2- and 12-weeks after repair were indeed 
dictated by the type of denervation injury in surgically repaired lacerated skeletal muscles.   
7.1 – Fibrosis  
 
  The response to muscle laceration is the development of fibrosis during repair. 
Fibrosis is a reactive process involving the activation of fibroblasts, endothelial cells and 
pericytes, leading to excessive collagen and chondroitin sulphate proteoglycan deposition, 
chiefly type 1 collagen and aggrecan. Collagen-1 and aggrecan is deposited by fibroblasts 
during repair for wound contraction. The resultant healed skeletal muscle functions well in 
crude terms representing a contractile structure bridged by a scar. It is not however 
inherently functional as a contractile structure under neural control. 
7.1.1- Preserved Intra-muscular Nerve Model 
 
PN has the lowest aggrecan and second lowest collagen expression level after 12-
weeks. This is due to the following factors: 
1) Down-regulation of myostatin, TGFb2, CTGF, R-spondin-1, galectin-1, HGF, IGF1 and 
Shh expression: Significant drop in expression of these proteins lead to reduction in 
expression of collagen-1 and aggrecan through both Erk1/2 and SMAD2/3 pathways in 
fibroblasts.  
2) Up-regulation of decorin expression: High decorin in PN induces quiescence in 
fibroblasts via up-regulation of p21. In addition, decorin core protein fragment Leu155-
Val260 binds to TGFb and prevents it from binding to the TGFb receptors. Decorin also 
binds to myostatin with its core protein, suppressing its activity. Similarly, decorin binds to 
CTGF using its leucine rich repeat residues 10-12 (Vial C et al, 2011). This prevents CTGF 
from binding to its receptor. All this leads to inhibition of SMAD phosphorylation and 
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reduction of collagen-1 gene transcription. High decorin expression in PN is induced by 
TGFb2 via CRE-like element in the P1 promoter of the gene, by CTGF (Vial C et al, 2011), 
and it is under neural control.  
3) Up-regulation of AMPK expression: AMPK disrupts SMAD2/3 association with p300 
and promotes proteosomal degradation of p300, thereby inhibiting TGFb-induced SMAD3 
phosphorylation and nuclear translocation, leading to reduced aggrecan and collagen 
production. AMPK is activated by high TAK1 (TGFb activated kinase-1). 
4) Up-regulation of EGF expression: EGF can reduce fibrosis via TGIF (TGFb-inducible 
factor). Activation of the Ras/MAPK pathway by EGF leads to the phosphorylation of the 
TGIF to inhibit Smads. This suppresses aggrecan and collagen-1 transcription further in PN. 
EGF also up-regulates MMP1 synthesis to degrade collagen at lesion site. 
5) Up-regulation of CNTF expression: CNTF increased acetylcholinesterase expression 
(Boudrea-Lariviere et al, 1996) to break down excessive acetylcholine released from nerve 
stumps, so reducing the activation of fibroblasts in vicinity. 
6) Up-regulation of Sirt1 expression: Sirt1 deacetylates the p65 subunit of   the NFkB 
complex at lysine 310, and inhibits the NF-κB signaling to activate the synthesis of 
collagen-1a in fibroblasts and immune cells  
7.1.2- Denervated Intra-muscular Nerve Model  
DN has the highest collagen and aggrecan levels at 15.76-fold and 7.69-fold more 
than the control respectively. This is due to the following reasons: 
1) Up-regulation of NT4 and GDNF: NT4 can bind to Trk receptors expressed by 
fibroblasts, stimulating them to proliferate and trans-differentiate into active myofibroblasts, 
leading to high collagen production via MAPK/Erk pathway (Palazzo E et al, 2012); 
fibroblasts also express RET receptors which are activated by GDNF binding, leading to 
increased in collagen-1a and aggrecan production  
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2) Up-regulation of TGFb2: Pulsatile release of TGF2 (Yang et al, 1999) induces the 
myofibroblast phenotype permanently (Hizz B et al, 2003). The continued maintenance of 
myofibroblast is due to the epigenetic memory in fibroblasts that have been exposed to 
TGFb (Chen et al, 2009), resulting in constitutive collagen-1 gene transcription. High 
TGFb2 expression in DN also attracts phagocytes and monocytes to remove dead cells and 
initiate muscle fibre regeneration (Ranges et al, 1987; Wahl et al, 1987, Wahl et al, 1988; 
Adams D et al, 1991; Reibman J et al, 1991). In addition, TGFb2 furthers up-regulates the 
expression of myostatin by reducing the furin expression in myoblasts, and via Foxo and 
SMAD2 signaling to promote fibrosis. 
3) Up-regulation of CTGF and TGFb2: CTGF protects aggrecan from aggrecanase 
degradation by binding to its globular domains in the extracellular matrix. This leads to 
accumulation of aggrecan in skeletal muscle, making the muscle very stiff and rigid and 
losing its isometric contractile function over time post-laceration. Also, both high TGFb2 
and CTGF expression in DN induce the synthesis of collagen-1 and aggrecan through two 
common Erk1/2 and SMAD2/3 pathways. TGFb2 also induces fibrosis via up-regulation of 
scleraxis in fibroblasts (Mendias CL et al, 2012). TGFb can further up-regulate the CTGF 
expression via the TGFb-inducible element in the CTGF-promoter region (Grotendorst, 
1997). CTGF expression is upregulated by high mechanical stress induced from muscle 
laceration via p38 binding to the stretch responsive element, GAGACC (Schild C et al, 
2002; Blom IE et al, 2002). 
4) Insufficient follistatin expression: Follistatin exerts significant anti-fibrosis effect in DN 
by sequestering myostatin and TGFb from its receptor and inhibits SMAD signaling. 
Follistatin expression is under neural control (Armand AS et al, 2003) and it is a downstream 
target of Wnt signaling. Wnt signaling is greatly reduced in denervated muscles by 
myostatin, CTGF and short Frizzled proteins (sFRPs). However the high follistatin 
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expression level in DN is insufficient to reduce the fibrosis-induced by myostatin, CTGF 
and TGFb2 because other fibrosis-inducing pathways are concurrently activated such as the 
angiotensin, NFkB and PDGF-α pathways. 
5) Up-regulation of myostatin: Stress induced from muscle laceration is transmitted via titin 
cap and p38 to increase myostatin expression. High myostatin level in damaged muscle can 
also stimulate fibroblasts to proliferate and differentiate to myofibroblast through SMAD 3 
signaling. Thus, the vicious cycle of TGFb2 and myostatin constitutively inducing the 
myofibroblasts to produce excessive collagen and proteoglycan at lesion site continues after 
12-weeks in DN. 
6) Leakage of acetylcholine from cut nerve into ECM: The fibroblasts in the endomysium 
can also synthesize collagen upon stimulation by acetylcholine release from crushed nerve. 
Expression of choline acetyl tranferase is up-regulated in nerve stumps by NT4 and GDNF 
but not CNTF, so excess acetylcholine is spontaneously released from nerve stumps; which 
then constantly activate the fibroblasts to synthesise collagen-1a at lesion site 
7) Glutamine release into ECM: Glutamine released from muscle proteolysis can also 
stimulate the collagen expression in fibroblasts. This is both pyrroline-5-carboxylate-
dependent and transport system L-dependent; 
8) Leucine release into ECM: Leucine released from protein degradation stimulates HGF 
production in fibroblasts. This leads to more fibrosis in DN because HGF increases collagen 
synthesis in fibroblasts through MEKl-mediated phosphorylation on the SSXS motif of 
Smad2, resulting in its nuclear accumulation and transactivating activity. 
9) Down-regulation of decorin expression: Drop in decorin levels increased the 
bioavailability of CTGF and TGFb2 binding to respective receptors and activation of the 
downstream SMAD signaling to increase collagen-1a and aggrecan synthesis in fibroblasts. 
10) Down-regulation of EGF expression:  Reduced levels of EGF lead to the activation of 
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Smads signaling which then increase aggrecan and collagen-1 synthesis in fibroblasts.  
11) Up-regulation of R-spondin-1, Galectin-1, HGF, IGF1 and Shh expression: Fibroblasts 
in DN proliferate faster than myoblasts and so they produced more collagen-1a and aggrecan 
due to high levels of myostatin, TGFb2 and CTGF as well as R-spondin-1, galectin-1, HGF, 
IGF1 and Shh. Galectin-1, a beta galactoside binding protein, binds to cell surface 
glycoconjugates of the fibroblasts, stimulating them to synthesize collagen-1 via p38 and 
Erk signaling. IGF1 increases aggrecan transcription in fibroblasts via PI3K signaling while 
Shh can induce aggrecan synthesis through Gli-mediated phospho-activation of SMAD2 and 
3. Vimentin stabilizes the collagen-1a mRNA before it is exported to the Golgi and ER. HGF 
can also increase collagen synthesis in fibroblasts through MEKl-mediated phosphorylation 
on the SSXS motif of Smad2, results in its nuclear translocation and transactivating activity. 
R-spondin-1, heparin-binding protein, binds to the LRP5/6 co-receptor and synergises with 
the Wnt3a to fibroblast proliferation.   
12) Down-regulation of AMPK expression: At low AMPK levels, SMAD2/3 binds to p300 
and promotes TGFb-induced SMAD3 phosphorylation and nuclear translocation, leading to 
more aggrecan and collagen production in fibroblasts. 
7.1.3- Re-innervated Intra-muscular Nerve Model 
RN has the lowest collagen (0.13-fold) and second lowest aggrecan (2.15-fold) levels 
compared to the control. This is due to the following reasons: 
1) Up-regulation of  PGC-1a expression: PGC-1a is a co-activator for PPAR-alpha and 
gamma. Upon ligand binding, PPAR heterodimerizes with retinoid X receptor and prevents 
the phosphorylated Smads from undergoing nuclear translocation, thereby intercepting 
TGFb–mediated signal transduction. In glomerular mesangial cells, PPARg agonist activated 
signaling leads to an upregulation of the Smad transcriptional co-repressor TGIF. 
Accumulated TGIF then binds to activated Smads and sequesters TGFb/Smad-mediated 
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gene transcription. Another mechanism of reducing muscle fibrosis mediated by PGC-1a is 
to inhibit myostatin activity via Gasp-1. Gasp-1 binds to myostatin through its cysteine 
repeat domains and inhibits its functions. PGC-1a expression is greatly increased in RN 
because the high stress induced from laceration activates the p38, which then phosphorylates 
and stabilizes the PGC-1a protein.  
2) Up-regulation of follistatin expression: Follistatin sequesters myostatin and TGFb from 
the respective receptors and inhibits SMAD signaling in fibroblasts. 
3) Up-regulation of AMPK expression: AMPK disrupts SMAD2/3 association with p300 
and promotes proteosomal degradation of p300, thereby inhibiting TGFb-induced SMAD3 
phosphorylation and nuclear translocation, leading to reduced aggrecan and collagen 
production.  
4) Up-regulation of CNTF expression: CNTF increased the acetylcholinesterase expression 
(Boudrea-Lariviere et al, 1996) to break down excessive acetylcholine released from nerve 
stumps, so reducing the activation of fibroblasts in vicinity. 
5) Down-regulation of CTGF, myostatin, HGF, Shh, IGF1 and R-spondin-1 expression: 
Reduction in expression of these proteins decreased collagen-1 and aggrecan production 
through both Erk1/2 and SMAD2/3 pathways in fibroblasts.  
Overall, RN has the lowest fibrosis status because it can inhibit initiation of gene 
transcription of pro-fibrosis factors via PGC-1a which is faster and more specific than the 
inhibitory binding effect between decorin and the pro-fibrosis factors to reduce their 
availability to respective receptors.   
7.1.4- Hypothesis Support  
Fibrosis is initially laceration-induced. It promotes massive increase in inhibitory 
aggrecan and collagen-1 leading to denervation. Denervation leads to more atrophy which in 
turn further aggravates the fibrosis in lacerated skeletal muscles (Fig. 22 and 23). 
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7.2 – Atrophy  
Muscle atrophy is divided into 2 different stages. Calpain-dependent proteolysis is 
involved in the early phase, while the lysosomal and ubiquitin-proteosome systems 
participate in the late phase. Both proteolytic pathways are increased in chronic denervated 
skeletal muscles. Muscle-specific E3 ubiquitin ligases, atrogin-1 and MuRF-1, drive the 
ubiquitin proteosome pathway mediated myofibrillar proteolysis (Edstrom E et al, 2007). 
The up-regulation of atrogin-1 and MuRF-1 can be Foxo, NFkB, p38, Erk or myogenin-
dependent. Complement-3 secreted from phagocytes and dying muscle fibres at lesion site 
can degrade fast myosin heavy chains in skeletal muscle reperfusion injury. It is also needed 
for rapid Wallerian degeneration and efficient clearance of myelin after acute peripheral 
nerve trauma.  Another important factor for loss of muscle mass is the reduced levels of 
IGF1, which activates Akt and mTOR phosphorylation to increase protein synthesis in 
muscle fibers. 
7.2.1- Preserved Intra-muscular Nerve Model 
PN has the lowest atrogin-1, MuRF1 and complement-3 expression levels after 12-
weeks. This is due to the following reasons:  
1) Atrophy in PN is AMPK-driven. AMPK induces muscle atrophy by promoting phospho-
activation of Foxo1 and Foxo3, which up-regulates synthesis of atrogin-1 and MuRF-1; 
AMPK also inhibits the mTOR pathway and p70S6K phosphorylation for protein synthesis.  
2) Up-regulation of decorin: Decorin inhibits atrophy via binding to myostatin with its core 
protein and sequestering myostatin from binding to its ActIIB receptor. This leads to 
inhibition of Foxo phosphorylation. 
3) IGF1 and CNTF inhibit atrophy through Akt signaling; Akt dephosphorylates Foxo1 and 
Foxo3, and prevents their nuclear translocation by sequestering them to the 14-3-3 scaffold ; 
IGF1 and CNTF can also activate mTOR and p70S6K phosphorylation to increase protein 
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synthesis (Wang and Forsberg, 2000); 
4) calpain-3 inhibits NFkB-induced atrophy; activation of NFkB by phosphorylation leads to 
NFkB translocation to the nucleus where it induces the transcriptional regulation of the 
MuRF1; it can also decrease IL6- induced muscle atrophy. 
5) Sirt-1 up-regulation inhibits NFkB and Foxo, resulting in enhanced protection against 
muscle atrophy. 
The calpain-3 level in PN is higher than DN and RN. The reasons are as follows: 
1) higher protein turnover in response to injured myofibers as calpain-3 is needed to activate 
myoD and myogenin for growth and differentiation of muscle cells (Berchtold et al, 2000). 
As calpain-3 is known to bind with titin, increased calpain-3 abundance at 12-weeks in RN 
and NegC may parallel to the amounts of recently formed titin from sarcomere synthesis 
(Sorimachi and Suzuki, 2001); 
2) high calcineurin expression, through the activation of NFAT, can increase the expression 
of calpain-3 as the calpain-3 promoter has a binding site for MEF2/NFAT heterodimers 
(Sorimachi et al, 1996). 
3) high availability of nitric oxide synthase (NOS), which up-regulate calpain-3 activity via 
calcium/calmodulin (Berchtold et al, 2000); 
4) the calpain-3 mRNA is stabilized by RNA-binding proteins, HuR and HuD. 
 
7.2.2- Denervated Intra-muscular Nerve Model 
It has the highest atrogin-1and MuRF1 expression levels after 12-weeks. This is due 
to the following factors:  
1) High myostatin level induces the expression of atrogin-1 and MuRF1 through Foxo-
dependent pathway; myostatin also auto-upregulates its transcription via p38 and Foxo 
signaling; 
2) High follistatin level cannot inhibit atrophy via binding myostain through its heparin 
89 
 
sulphate domain at the extra-cellualr matrix because Foxo-independent pathways are 
activated to increase atrogin-1 and MuRF1 expression; 
3) High NT4 and GDNF levels did not decrease atrophy because Foxo-independent 
pathways are activated to induce atrophy; Foxo-independent pathways to induce atrophy 
include activation of p38 to increase atrogin-1 expression, NFkB and Erk1/2 to increase 
MuRF1 expression; 
4) Low IGF1 level leads to inhibition of Akt phosphorylation and mTOR activation, 
resulting in decreased protein synthesis;   
5) A lot of dying muscle fibers leads to high complement activation, which then activates 
more apoptosis of muscle fibers via caspase-3. Overall, DN is in the most severe catabolic 
state at 12-weeks post-repair compared to other groups. 
7.2.3- Re-innervated Intra-muscular Nerve Model 
It has the highest complement-3 expression level after 12-weeks, while its atrogin-1 
and MuRF1 levels are intermediate between PN and DN. This is because atrophy in RN is 
driven by myostatin, myogenin and AMPK. PGC-1a inhibits Foxo3 and so reduces the 
expression atrogin-1 and MuRF1. However, high PGC-1a expression cannot totally inhibit 
atrophy because p38 and Erk1/2 can up-regulate atrogin-1 and MuRF1 expression on their 
own. High myogenin expression in RN is mediated by HDAC4 upon denervation, while the 
high complement-3 expression is induced by the Wallerian degeneration.  
7.2.4- Hypothesis Support 
Atrophy is initially denervation-induced. It is both myostatin and myogenin-driven in 
DN and RN, but it is AMPK-driven in PN. Atrophy also arises from reduction in protein 
synthesis due to inhibited Akt and mTOR signaling from significant drop in IGF1, PGC-1a 
and CNTF levels; and concurrent increase in muscle proteolysis due to high expression of 
atrogin-1, MuRF1 and complement-3. Huge amounts of glutamine and leucine released from 
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protein degradation promotes further fibrosis, which leads back to chronic denervation and 
the cycle repeats itself (Fig.23). 
7.3 – Myogenesis  
Muscle laceration releases HGF from the ECM. HGF activates the satellite cells to 
down-regulate Pax7 and increase the expression of MyoD and myf5. The satellite cells then 
proliferate into myoblasts, then differentiate and fuse to form new adult myofibers to replace 
dead myofibers. Skeletal muscle regeneration requires also energy for activation of satellite 
cells and myoblast differentiation into adult myofibers. This needs active mitochondrial 
biogenesis regulated by PGC-1a. Respiration-deficient myoblasts devoid of mitochondria 
fail to differentiate. Also, inhibition of mitochondrial protein synthesis with chloramphenicol 
prevents the differentiation of myoblasts into myotubes. 
7.3.1- Preserved Intra-muscular Nerve Model 
PN had better myogenesis based on histology. It had more mature, fully 
differentiated adult muscle fibers with large cross-sectional area and multiple nuclei at the 
periphery. The reasons are as follows: 
1) Denervation up-regulates myoD expression in PN via the activating the distal regulatory 
region and proximal regulatory region of its promoter. High myoD expression induced p21 
and Rb synthesis to inhibit apoptosis of myoblasts. MyoD induces permanent cell cycle 
arrest by up-regulating p21 and p300 and activates muscle-specific gene transcription in 
myogenesis.  
2) Increase in decorin, EGF, CNTF, Sirt1 expression coupled with lower TGFb2 and CTGF 
levels promoted significant myogenesis in PN. Decorin regulate TGF-β availability during 
skeletal muscle differentiation. Once myoblasts differentiate into myotubes, the decorin 
expression in the ECM is increased, and decorin binds to TGFb and myostatin to sequester 
the proteins to the ECM. This decreases the availability of TGFb2 and myostatin to their 
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transducing receptors, thus allowing myogenesis (Brandan et al, 2008). When the terminal 
differentiation of myoblasts into adult muscle fiber is completed, TGF-β binds to its 
transducing receptors and activates the Smad dependent pathway. It also binds to decorin 
and LRP, resulting in an activation of the PI3K dependent pathway. These two signaling 
pathways synergize to inhibit abnormal myogenesis. Decorin is also involved in myoblast 
migration (Olguin et al, 2003). It represses myoblast migration to permit skeletal muscle 
differentiation, independent of chemotactic growth factors. Decorin has also been 
demonstrated to increase expression of follistatin (Zhu J et al, 2007); so PN having higher 
decorin up-regulates follistatin expression simultaneously; PN has significantly greater 
myogenesis due to the higher follistatin expression; follistatin stimulated the myoblasts to 
differentiate via up-regulating myoD, myf5 and myogenin; it also blocks myostatin and 
TGFb2 activity, and enhances neo-vascularisation. 
3) CNTF can also increase the differentiation of muscle satellite cells (Chen et al, 2005) via 
activation of STAT3 (Kirsch et al, 2003). Satellite cells proliferate in response to 
denervation. This process is stimulated by Sirt1- induced reduction of p21 activity. Sirt1 can 
also increase proliferation and differentiation of myoblasts as it deacetylates and inhibits 
NFkB, and this indirectly up-regulates myoD expression . Also, Sirt1 can activate PGC-1a to 
increase myoD transcription (Amat R et al, 2009). In addition, activation of p38 by stress 
from muscle laceration also results in enhanced PGC-1a expression and mitochondrial 
biogenesis. Next, PN has lower NAD+ levels as the IM nerve is intact, so Sirt1 and AMPK-
1a cannot inactivate Mef2a, this promotes myogenesis. 
4) Decreased CTGF and TGFb2 expression allow more terminal differentiation of myoblasts 
into mature muscle. This is because TGF-2 inhibits fusion of myoblasts via down-
regulating the expression of cdk6 and cyclin E-associated cdk2 activity (Tsubari et al, 1999), 
and it synergises with CTGF to inhibit the terminal differentiation of myoblasts into mature 
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muscle cells by blocking the expression of myoD and myogenin. This is achieved by 2 
mechanisms: a) SMAD3 has been shown to bind to the bHLH region of myoD, interfering 
with myoD/E protein dimerization and subsequent cooperative binding to E-box DNA; b) 
SMAD3 also can bind with MEF2a, which prevent the association of the myoD/E47 dimer 
with Mef2a, resulting in the repression of muscle-specific gene expression.  
5) High EGF levels in PN further enhance satellite cell proliferation and myoblast migration 
for fusion to become mature muscle fibers via Akt signaling pathway. 
 
7.3.2- Denervated Intra-muscular Nerve Model 
Denervation significantly inhibited myogenesis in DN as DN has more immature 
muscle fibers with small size and central nuclei at lacerated site. The reasons are listed 
below:  
1) Depletion of satellite cell pool because the satellite cells died by apoptosis under chronic 
denervation, and myostatin inhibits satellite cell renewal through Erk1/2 mediated 
downregulation of Pax7;  
2) Inhibition of myoblasts to fuse and differentiate to form mature myofibers as there is 
increase in myostatin, Id1, TGFb2 and CTGF expression. Myostatin, TGFb2, Id and CTGF 
down-regulate myoD expression. Myostatin also induces cyclin D degradation via PI3K to 
cause cell cycle arrest. It then inhibits the satellite cell activation and proliferation, as well as 
myoblast proliferation and differentiation via up-regulating p21. Also, myostatin decreases 
myotube formation via down-regulation of cdk6 and cyclin E-associated cdk2 activity 
(Tsubari et al, 1999). Myostatin also inhibits mTOR signaling and so reduces protein 
synthesis in myoblasts. 
3) New proliferating myoblasts can only fuse with existing denervated muscle fibers but not 
with each other to form new fibers (Fig 22); 
4) High levels of aggrecan and collagen-1 in the scar region inhibit myoblast migration; 
93 
 
5) Downregulation of calpain-3 leads to over-activation of caspase-3, calpain-1 and 2, 
inducing excessive myoblast apoptosis;  
6) Decreased PGC-1a expression leads to less mitochondrial biogenesis activity;  
7) Denervation increases nuclear NAD+ levels and this induces Sirt1 to deacetylate and 
inactivate myoD, and also high AMPK expression in DN can inactivate Mef2a, so blocking 
satellite cell activation and subsequent muscle differentiation (Araki et al, 2004). 
8) High NT4 and GDNF expression did not improve myogenesis in DN because they mainly 
exerted pro-fibrosis effects (Appendix 12).  
9) Denervation decreases muscle mitochondrial content and increases mitochondrial 
permeability, leading to elevated apoptosis in skeletal muscle.  
Hence there is less viable myoblasts available to fuse and form mature adult muscle fibers. 
The newly regenerated adult muscle fibers are often small in size and scarce in number.  
7.3.3- Re-innervated Intra-muscular Nerve Model 
Myogenesis in RN is mainly promoted by R-spondin-1, Shh and galectin-1, as it has 
the highest expression levels of the 3 markers. Shh promotes proliferation and differentiation 
of myoblasts via Erk and Akt signaling. Also, the re-activation of Shh expression in adult 
skeletal muscle after injury can induce angiogenesis via upregulation of VEGF and SDF-1a. 
Galectin-1 promotes both myoblast fusion and muscle re-innervation following laceration, 
increasing the available myoblasts to form new myofibers. R-spondin-1 up-regulates the 
expression of myf5 to initiate myoblast differentiation via Wnt/beta-catenin pathway. 
7.3.4- Intermediate Filaments  
The expression of desmin during skeletal muscle regeneration indicates the presence 
of myoblasts (Bassaglia and Gautron 1995) and newly formed myotubes (Duguez et al, 
2003). The higher expression of desmin in PN at 12-weeks corresponds to a higher synthesis 
of sacrcomeric proteins and intense fusion of myoblasts to form myotubes (Duguez et al, 
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2003). This is confirmed in immunohistochemistry staining of longitudinal sections of 
medial gastrocnemius muscle (Fig 4). The increase in desmin expression is crucial for the 
satellite cell activation and myoblast proliferation (Bockhold et al, 1998; Duguez et al, 
2003). Also, desmin stabilizes mitochondria positioning in cells, and keep the myofibrils in 
register. Vimentin was used as a scar marker because it is expressed by myofiber early in 
development and shortly after injury at 2-weeks, then it is rapidly down-regulated during 
muscle differentiation and it is replaced by desmin. Vimentin is important for stabilization of 
collagen-1 mRNA in fibroblasts and retrograde importin-Erk signaling in regenerating 
neurons (Hanz et al 2003).  Nestin prevents cdk5-induced apoptosis by sequestering 
cdk5/p35 complexes in regenerating neurons. The orchestrated dynamic expression of 
intermediate filaments in PN implies that intact innervation is crucial to drive the proper 
myogenic lineage commitment of the muscle precursor cells during muscle repair. 
7.3.5- Hypothesis Support 
Decrease in myogenesis is denervation-induced, then aggravated by fibrosis and 
atrophy, resulting in the loss of muscle mass and size. Chronic denervation leads to 
incomplete terminal differentiation of young myofibers into mature adult fibers to replace 
dead muscle fibers. The reduction in size of muscle fibers is due to myostatin inhibiting 
protein synthesis via mTOR signaling, while the decrease in number of mature muscle fibers 
is due to myostatin inhibiting satellite cell renewal via down-regulation of Pax7. 
7.4 – Fiber Transformation   
Denervation can alter the isometric contractile force in regenerating skeletal muscle. 
This process is called fiber transformation as the original expression levels of the contractile 
proteins are permanently modified after muscle repair. 
The adult rat medial gastrocnemius expresses both fast and slow myosin heavy 
chains in the ratio of 1:1, and also both fast and slow troponin-I isoforms in the ratio of 12:1. 
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Fiber transformation in MG after denervation is denoted by a significant reduction in myosin 
heavy chain-2b fibers and a corresponding increase in slow myosin heavy chains expression 
compared with those of normal subjects. This leads to the regenerating MG muscle having 
weaker contractile properties than the original undamaged muscles. The regenerating rat 
myotubes initially express both slow and embryonic myosin heavy chains. When the 
myotubes get re-innervated by fast motor neurons, the embryonic myosin heavy chains are 
subsequently replaced by fast myosin heavy chains. Innervation is necessary to maintain fast 
and slow troponin-I expression since it is greatly increased in DN at 2-weeks after 
laceration. The expression of both the myosin heavy chain and troponin-I isoforms is 
dictated by the following factors:   
1) Myogenin and Mef2a control the expression of slow myosin heavy chain while myoD 
drives the expression of fast myosin heavy chain.  
2) Myostatin regulates the fiber type composition of skeletal muscles by controlling myoD 
and MEF2a gene expression. It up-regulates Mef2a after denervation to promote the slow 
muscle fiber expression, and the reverse is true for fast muscle fiber expression after the 
muscle is re-innervated.  
3) TGFb inhibits the expression of all myosin heavy chain isoforms, while Shh and NT4 
specify the slow fiber type.  
4) CNTF specifies both fast and slow myosin heavy chains.  
5) Sirt1 and PGC-1a control gene expression of slow fiber genes. PGC-1a activates MEF2 to 
up-regulate slow myosin heavy chain and slow troponin-I expression.  
6) IGF1 terminates the expression of embryonic myosin heavy chain once the regenerating 
muscle is innervated by the fast motor neuron. It also enhances the expression of fast myosin 
heavy chain -2B via GSK3B signaling.  
7.4.1- Preserved Intra-muscular Nerve Model 
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PN retained most of its fast myosin heavy chain and fast troponin-I expression after 
12-weeks due to higher CNTF expression and lower atrogin-1, MuRF1 and complement-3 
levels, as well as significant reduction in myostatin and TGFb2 expression. 
7.4.2- Denervated Intra-muscular Nerve Model 
The high expression of embryonic myosin heavy chain at 12-weeks in DN indicated 
that intact innervation is still absent. Also, the down-regulation of embryonic myosin heavy 
chain at 12-weeks implied that myoblasts in DN had differentiated (Miyabara EH et al, 
2005). The high levels of myostatin, atrogin-1, complement-3, MuRF-1 and TGFb2 
expression at 12-weeks greatly inhibit the expression of fast myosin heavy chain and fast 
troponin-I. The decreased levels of PGC-1a coupled with the increased expression of slow 
myosin heavy chain and slow troponin-I that retain lower oxidative capacity, and the 
decreased amount of mitochondria in cut muscle lead to loss of isometric contraction in the 
DN rats.  
7.4.3- Re-innervated Intra-muscular Nerve Model 
RN has also retained its myosin heavy chain-2b and fast troponin-I expression more 
than DN at 12-weeks post-repair due to reduction in expression of   myostatin, TGFb2, 
atrogin-1, MuRF-1 and complement-3. 
7.4.4- Hypothesis Support  
With the intramuscular nerve preserved intact (PN), there is decrease in fiber 
transformation than DN. DN had lost most of its fast myosin heavy chain-2B as fast myosin 
heavy chains are less resistant to atrophy. 
7.5 – Intra-Muscular Nerve Regeneration 
The intra-muscular nerve can regenerate on its own after the muscle laceration. The 
success of muscle re-innervation depends critically on the growth environment in the distal 
nerve stump following the removal of axonal and myelin debris. Regenerating axons grow 
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toward denervated muscles within the endoneurial tubes formerly occupied by intact axons 
and their myelin sheaths. Few regenerating axons can successfully cross the gap between the 
proximal and distal nerve stumps even after micro-surgical repair due to the inhibitory 
collagen and proteoglycan deposited at lesion site.  
7.5.1- Preserved Intra-muscular Nerve Model 
PN expressed the highest GAP43 expression level after 12-weeks even though the 
intra-muscular nerve is preserved intact. The intact IM nerve leads to higher EGF, decorin 
and galectin-1 expression than DN. EGF synergises with FGF2 to inhibit TGFb2-induced 
apoptosis of Schwann cells. Decorin inhibits the pro-fibrotic activity of TGFb2. 
Administration of decorin to injured sites in the adult rat brain and spinal cord suppresses 
expression of aggrecan and promoted axon growth across adult spinal cord injuries. Decorin 
also reduces EGFR-induced synthesis of aggrecan and myelin-associated inhibitors of axon 
growth via RhoA/ROCK pathway. Oxidized galectin-1 from macrophages, fibroblasts and 
Schwann cells promotes IM nerve regeneration via neuropilin-1 signaling. Neuropilin-1 is a 
receptor for motor neuron guidance and survival. The strong positive correlation between 
HN1 expression and GAP43 level indicated the high abundance of regenerating motor 
neurons in PN.    
7.5.2- Denervated Intra-muscular Nerve Model 
It has the lowest GAP43 expression level after 12-weeks. High NT4 and GDNF did 
not improve IM nerve regeneration in DN due to aggressive fibrosis induced by TGFb2, 
myostatin and CTGF which inhibited axonal regeneration, and high complement-3 levels 
which destroyed the newly regenerating axons. Hence the Schwann cells cannot re-connect 
and re-myelinate the severed nerve stumps.  
7.5.3- Re-innervated Intra-muscular Nerve Model 
RN tells us that intact nerve sheaths are important for muscle regeneration after 
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laceration because if the nerve sheath is present, retrograde flow of neurotrophic factors and 
axonal guidance cues can occur to promote muscle re-innervation which then inhibits 
atrophy. Also, the intact nerve sheaths enhance correct targeting of nerve to specific muscle 
to re-establish functional neuromuscular junctions in midst of muscle scar. RN has better IM 
nerve regeneration than DN because it expressed high HGF to induce the proliferation of 
spinal motor neurons, promote survival of regenerating motor neurons and denervated 
Schwann cells. It also has high Shh level to stabilize structural and functional integrity of 
peripheral nerve.  
7.5.3.1-Relevance of RN model to clinical practice: 
Risk rates for crushed peripheral nerve injury in people incurring limb trauma are low 
(Sahjian et al, 2009). Crush skeletal muscle injuries have the highest rate of associated intra-
muscular nerve injury. The overall incidence is 0.1% as the crush skeletal muscle injury is 
unpredictable. This model has acknowledged limitations. It can be difficult to replicate a 
clinical scenario of random tissue injury (ie muscle, nerve, veins and bone), nevertheless our 
reductionist model would better able isolate the injuries secondary to the defined markers 
studied in this thesis. 
7.5.4- Hypothesis Support 
Intra-muscular nerve regeneration in PN is better than DN as PN has the highest 
GAP43 expression level at 12-weeks (0.85-fold) while DN has the lowest GAP43 
expression (0.59-fold).  
This great reduction in GAP43 activity in DN is due to aggressive fibrosis which 
inhibited axonal regeneration and high complement-3 (6.61-fold) expression which 
destroyed the newly regenerating axons. This contributes to a reduction in number of axons 
that can eventually reach the denervated segment of the muscle fibers via the network of 
endoneurial tubes formerly occupied by intact axons and their myelin sheaths. However, no 
99 
 
nerve sprouts were detected at 12-weeks in all groups. The reasons are listed below: 
1) Excessive high levels of collagen-1 and aggrecan in the remodeled ECM inhibit IM nerve 
regeneration;  
2) High expression of immature neurotrophins, truncated Trk receptors and p75NTR in the 
injured neurons resulted in apoptosis of motor neurons upon ligand binding (Williams G et 
al, 2005); 
3) High expression of IGFBP4 and IGFBP5 inhibits IGF1-mediated axon sprouting; 
4) Insufficient levels of decorin and follistatin expressed from Schwann cells and myoblasts 
to inhibit pro-fibrotic activity of TGFb2, CTGF and myostatin;  
5) Down-regulation of MMPs and TIMPs to degrade the excessive collagen at lesion site; 
6) Lack of electrical stimulation as polyneuronal innervation of muscle fibers is activity-
dependent (Skouras E 2011). 
7.6 – Targets to intervene for better muscle recovery after laceration (clinical 
relevance) 
The targets include EGF, HGF, decorin, follistatin, aggrecan, atrogin-1, MuRF-1, 
IGF-1, CNTF, NT4, GDNF, AMPK, PGC-1a, Sirt1, myostatin, Sonic hedgehog, CTGF, 
galectin-1, R-spondin-1and TGFb2. The expression trends of these targets are statistically 
significant at both 2- and 12-weeks, and they can modulate the fibrosis and atrophy during 
muscle repair via multiple signaling pathways. They can synergise or antagonize each 
signaling pathways.  
Firstly, to reduce fibrosis in skeletal muscle after laceration, we can inhibit pro-
fibrosis effect of TGF-1 and myostatin either by suppressing the initiation of gene 
transcription or by altering the mRNA stability. For example, TGFb mRNA expression is 
reduced by anti-sense oligonucleotide, interferon-gamma and anti-oxidants (a-tocopherol). 
Another approach is to directly target circulating TGFb by using anti-TGFb anti-serum or 
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the use of chimeric protein composed of the extracellular domain of the TGFb type II 
receptor linked to the Fc portion of IgG that binds and inactivates TGFb. Other options 
include inhibiting the downstream SMAD phosphorylation in TGFb signaling by using 
small molecules such as trichostatin A (histone deacetylase inhibitor) and halofuginone.  
Also, we need to decrease the myofibroblast activation to reduce fibrosis. This is 
achieved by using thiodigalactoside to disrupt the interaction between galectin-1 and 
glycoconjugates at the cell surface of fibroblasts. Next, we can use acetylcholine receptor 
inhibitors to block acetylcholine-dependent activation of fibroblasts to secrete collagen-1 at 
distal nerve stumps.   
Secondly, to minimize atrophy of lacerated skeletal muscle, we can use proteosome 
inhibitor, bortezomib, to inhibit Foxo and NFkB- induced atrogin-1 and MuRF-1 activity. 
We can also use Class II histone deacetylase inhibitors to ameliorate myogenin-induced 
atrogin-1 and MuRF-1 gene transcription.    
 Thirdly, combinatorial neurotrophic factor administration of IGF1, NT3, FGF2 and 
BDNF to lacerated skeletal muscle can be used to enhance neuronal survival, promote axon 
regeneration through the scar tissue and increase correct targeting of intra-muscular nerve in 
skeletal muscle post-laceration. Also, it is technically challenging to repair the damaged 
nerve in lacerated skeletal muscles by micro-surgery post-trauma and impossible to do so 
when the nerve-muscle gap is more than 3mm wide. Hence artificial nerve conduits or 
nerve-muscle grafts can be employed to aid the subsequent re-innervation of the lacerated 
skeletal muscle. This will greatly decrease muscle fibrosis and atrophy during the recovery 
phase.  
Lastly, we can use AMPK activators (metformin, 2-deoxyglucose, AICAR), PPAR-
gamma agonists and Sirt1 agonists to activate AMPK, PPAR-gamma, Sirt1 respectively in 
lacerated skeletal muscle as they are the master regulators of multiple downstream targets 
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involved in fibrosis, atrophy and myogenesis such as myoD, NFkB, Foxo, Mef2a, SMAD7 
and p300. This must be done at the correct time-point post-laceration to achieve desired 
outcomes. For example, we can start with Sirt1 agonists at 3 days post-laceration to expand 
the satellite cell pool, then switching to the Sirt1 inhibitors at 2-weeks to allow the 
proliferating myoblasts to differentiate to mature myofibers to replace the dead muscle 
fibers.  
8.  CONCLUSION    
 
 This study offers a rationale for repairing the concomitantly cut intra-muscular nerve 
in lacerated skeletal muscle, in addition to epimysial suturing of the muscle cut ends. The 
dynamic orchestrated expression of intermediate filaments, myogenic factors, muscle 
atrophy factors, fibrotic factors and neurotrophic factors in various treatment groups at the 2 
time-points supports our hypothesis. It is important to repair the damaged nerve which is 
present in a lacerated skeletal muscle as the integrity of the nerve can modulate the 
functional recovery of the lacerated muscle. This is evident when comparing the severity of 
fibrosis formation at the lesion site and the extent of reversible and irreversible muscle 
atrophy and denervation between PN and DN at 12-weeks post-surgery. However, repairing 
a damaged nerve by micro-anastomosis is not sufficient to decrease severity of the muscle 
atrophy, to reduce the extent of fibrosis between two muscle stumps, and to restore the 
isometric contractile properties of the muscle. Appropriate anti-fibrosis agents, anti-atrophy 
drugs and biological axonal guidance cues must be administered at correct dosage and at 
very early stage post-trauma to minimize the irreversible activation of myofibroblasts, 
decrease the transcription of muscle atrophy genes and loss of isometric contraction.  
We identified several potential endogenous biological targets which can improve 
both myogenic and neurogenic recovery across the lesion site to avoid irreversible muscle 
denervation and atrophy based on the distinct gene expression profiles in each skeletal 
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muscle laceration model. In brief, our results showed that the integrity of the intra-muscular 
nerve can regulate fibrosis, atrophy, intra-muscular nerve regeneration, fiber type 
transformation, and myogenesis across the lesion site. The relationship is depicted in Fig 22 
and 23. 
 
Figure 22. Possible repair cycle in a concomitant skeletal muscle laceration and 
intramuscular nerve damage. Although the skeletal muscle can regenerate itself post-
laceration, denervation can lead to irreversible atrophy and fibrosis at the lesion site. Firstly, 
TGFb2, myostatin and CTGF can inhibit the proliferation and differentiation of the 
myoblasts. Fusion of myoblasts is also inhibited by excessive collagen-1 and aggrecan 
deposited during extracellular matrix remodelling, initiated by myofibroblasts, infiltrating 
macrophages, neutrophils, surrounding endothelial cells and platelets. In addition, atrogin-1, 
MuRF-1 and complement-3 degrade both the young myotubes and the regenerating nerves. 
Both aggressive fibrosis and severe atrophy then further resulted in chronic denervation. 
Thus, less number of viable myoblasts is available to mature into adult muscle fibers to 
replace the dead fibers. Also, the differentiated myoblasts can only fuse with existing muscle 
fibers, not with each other. Hence, the newly regenerated adult muscle fibers are often small 





                  
 
 
Figure 23. Skeletal muscle laceration and cut intra-muscular nerve post-trauma (as in the 
DN model) can cause severe fibrosis at laceration site, leading to chronic denervation, 
aggressive muscle atrophy and permanent fiber type transformation, and finally resulting in 
poor muscle functional recovery. The vicious cycle repeats itself when the damaged nerve 
remains unrepaired. All three processes are inter-dependent, mutually inclusive and occur 
simultaneously. The integrity of the intra-muscular nerve after muscle laceration will govern 




9. LIMITATIONS OF THE STUDY 
 The study was limited by various factors. Most were unavoidable due to the nature of 
the experiments with animal studies and the availability of resources and time. A few are 
noted below for future work.  
9.1-Why was the laceration model simulated with a sharp cut? 
To avoid variations in muscle damage, a sharp laceration was used over a blunt 
laceration. This blunt model would have increase damage away from the lacerated site 
which may be unknown to us, and can affect the results. This is therefore only a simulated 
model of laceration. (Pereira et al., 2008, 2010) 
9.2-Why were only 2 time points studied, and why 2-weeks and 12-weeks? 
  We were comparing the stage of reversible muscle atrophy (~2week) and the 
irreversible state (~after 3 months) (Fu and Gordon, 1995, Fnkelstein et al., 1993). 
104 
 
9.3-Why was the nerve crushed used as a model to simulate nerve repair? 
This was an alternative model, again a simulation, as it was difficult to repair the 
intramuscular nerve in a rat. The intramuscular nerve is crushed damaging the axons but 
preserving the nerve sheath intact. Electrical stimulation was used to confirm that there was 
axonal damage, while integrity of the nerve sheath was also assessed to confirm continuity.  
This model allows for axonal regeneration within the nerve sheath and therefore can be 
compared with the DN where nerve and axonal regeneration may be more random, with the 
possibility of nerve sprouting from a neighbouring muscle which could be inappropriate. 
This also altered the MHC profile as shown previously (Pereira et al., 2010). 
9.4-Why use medial gastrocnemius, not soleus or plantaris or other muscles? 
 In an experimental muscle model in an animal given the ethic requirements, the 
medial gastrocnemius is the most common muscle used in experiments, as it avoid the loss 
of mobility in the animal, given that the animal can still function the foot, with the lateral 
gastrocnemius and the soleus. The medial gastrocnemius is also a large muscle and that 
provides sufficient tissue for our study.  
 
10. SUGGESTIONS FOR FUTURE WORK 
 Several suggestions are recommended for future work. Firstly, there is a need to 
assess suitable biological endogenous protein inhibitors and synthetic drug inhibitors for 
anti-fibrosis, anti-atrophy, pro-muscle re-innervation effects in animal models of skeletal 
muscle repair after trauma.  The second potential area of research is to establish skeletal 
muscle-fibroblast-neuron co-culture system or skeletal muscle-fibroblast-endothelial cell-
neuron co-culture system, which can be used for drug dosage studies. This is a better 
alternative to the animal model because it has more control of focal injury, has much less 
background noise arising from protein-protein interactions between different organs. In 
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addition, animal models have a large variability in genetic polymorphisms, and require large 
sample sizes for adequate power in statistical analysis. A third suggested model is to use 
siRNAs in either animal models or cell culture systems to inhibit collagen-1a, atrogin-1, 
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Appendix 1. List of TaqMan primers used in the real-time-PCR Assays 
No Target Catalogue No (Amplicon size / bp) 
1 Neurotrophic factor-4, NT-4 Rn01645105_m1(128) 
2 Glial derived neurotrophic factor,   GDNF Rn00569510_m1 (122) 
3 Ciliary neurotrophic factor CNTF  Rn00755092_m1(83) 
4 Insulin-like growth factor, IGF1 Rn00710306_m1 (69) 
5 Hepatocyte Growth Factor, HGF Rn00566673_m1 (139) 
6 Epidermal Growth Factor,EGF Rn00563336_m1 (93) 
7 Sonic hedgehog, Shh Rn00568129_m1 (100) 
8 MyoD Rn00598571_m1 (85) 
9 Myogenin Rn00567418_m1 (55) 
10 MEF2A Rn01478096_m1 (118) 
11 Desmin Rn00574732_m1 (78) 
12 Vimentin Rn00579738_m1 (105) 
13 Nestin Rn00564394_m1 (78) 
14 Atrogin-1 Rn00591730_m1 (61) 
15 MuRF-1 Rn00590197_m1 (56) 
16 Peroxisome proliferator activated receptor-gamma co-
activator, alpha, PGC-1 
Rn00580241_m1 (94) 
17 Sirt-1 Rn01428093_m1 (81) 
18 Myostatin Rn00569683_m1 (67) 
19 Calpain-3 Rn 00482978_m1 (96) 
20 Complement 3 Rn00566466_m1 (72) 
21 AMP-activated protein kinase alpha 1 subuint, AMPK Rn00569558_m1 (72) 
22 Follistatin Rn00561225_m1 (80) 
23 Transforming Growth Factor beta 2, TGF2 Rn00579674_m1 (95) 
24 Collagen Type 1 alpha Rn01463848_m1 (115) 
25 aggrecan (chondroitin sulphate proteoglycan-1) Rn00573424_m1 (74) 
26 Galectin-1 Rn00571505_m1 (98) 
27 Decorin Rn01503161_m1 (101) 
28 Fast skeletal troponin-I Rn00437157_g1 (62) 
29 Embryonic myosin heavy chain 3 Rn00561539_m1 (63) 
30 Fast skeletal myosin heavy chain 4  Rn01496087_m1 (65) 
31 Slow skeletal myosin heavy chain 7 Rn01536269_m1 (111) 
32 Slow skeletal troponin-I Rn00567843_m1 (129) 
33 Lamin A Rn00572764_m1 (72) 
34 Hematological and neurological expressed-1, HN-1 Rn01466868_g1 (137) 







Appendix 2. List of antibodies used for immunohistochemistry and western blot  
Antigen Host Suppli
er 
Cat No.  Dilution Antigen retrieval  
vimentin mouse SC sc-6260 1:500 Microwave 20min, 
0.01M citrate buffer, 
pH6.1 (Dako);  
Milestone Mega T/T 
oven, Program 21 
desmin mouse SC sc-52326 1:500 Microwave 20min, 
0.01M citrate buffer, 
pH6.1 (Dako);  
Milestone Mega T/T 
oven, Program 21 
nestin mouse SC sc-33677 1:500 Microwave 20min, 
0.01M citrate buffer, 
pH6.1 (Dako);  
Milestone Mega T/T 
oven, Program 21 
galectin-1 rabbit A ab25138 1:200 Microwave 20min, 
0.01M citrate buffer, 
pH6.1 (Dako);  
Milestone Mega T/T 
oven, Program 21 
R-spondin-1 mouse RDS 422407 1:200 Microwave 20min, 
0.01M citrate buffer, 
pH6.1 (Dako);  
Milestone Mega T/T 
oven, Program 21 
alpha tubulin mouse SC sc-5286 1:1000 NA 
p38 rabbit CST 9212 1:1000 NA 
phospho-p38 rabbit CST 9211 1:1000 NA 
Erk1/2 rabbit CST 9102 !:1000 NA 
phospho-Erk1/2 rabbit CST 9106 1:1000 NA 
TGF2 rabbit SC sc-90 1:1000 NA 
connective tissue 
growth factor, CTGF 
mouse RDS MAB660 1:1000 NA 
alpha smooth muscle 
actin 
mouse Sig A2547 1:1000 NA 
SMAD2 and 3 rabbit SC sc-8332 1:1000 NA 
phospho-SMAD2 
and 3 
goat SC sc-11769 1:1000 NA 
Myogenin goat SC Sc-31945 1:1000 NA 
myoD rabbit SC Sc-304 1:1000 NA 
slow myosin heavy 
chain 
mouse Sig M8421 1:50,000 NA 
fast myosin heavy 
chain 
mouse Nov NCL-MHC 1:50,000 NA 
 
Suppliers  
SC – Santa Cruz; CST – Cell Signaling Technology; RDS – R& D Systems; A – Abcam  





Appendix 3. Recipe for casting SDS-PAGE gels 
 












Mass of glycine (g) 0.11 0.11 0.11 0.11 0.11 
 
Volume of 1.5M Tris + 0.4% 
SDS pH8.8 buffer ( mL) 
3.75 3.75 3.75 3.75 3.75 
Volume of 10% SDS (mL) 1 1 1 1 1 
Volume of MQ water (mL) 1.51
8 
----- ----- ----- ----- 
Volume of 100% glycerol (mL) 6 6 6 4.50 4.50 
Volume of 40% Bis-
Acrylamide mix (mL) 
3 3.75 4.50 5.25 6 
Volume of 10% APS (µL) 120 120 120 120 120 
Volume of TEMED (µL) 24 24 24 24 24 
Total vol (mL) 15 15 15 15 15 

























Appendix 4. Molecular weights of Protein Targets (based on antibody data sheets) 
 
No Protein Molecular weight /kDA 
1 galectin-1 14 
2 TGFb2 25 
3 -SMA 42 
4 CTGF 38 
5 desmin 53 
6 vimentin 57 
7 Slow myosin heavy chain 220 
8 Fast myosin heavy chain-2B 220 
9 p38 38 
10 phospho-p38 43 
11 ERK1 44 
12 ERK2 42 
13 phospho-ERK1 44 
14 phospho-ERK2 42 
15 SMAD2 60 
16 SMAD3 50 
17 phospho-SMAD2 60 
18 phospho-SMAD3 50 
19 -tubulin 55 
20 R-spondin-1 39 
21 myogenin 34 




























Appendix 5. Relative Quantification (RQ) data 
RQ values are shown in means and standard deviation, n=3 per treatment group. 
Post Repair Week:  2 Weeks     
Group NegC PosC DN PN RN 
N 3 3 3 3 3 
 EGF 0.561 (0.024) 1.247 (0.041) 0.521 (0.016) 1.1400 (0.021) 0.2826 (0.001) 
 HGF 3.431 (0.015) 0.0317 (0.000) 2.3376 (0.048) 7.5483 (0.037) 1.2353 (0.093) 
 Galectin-1 0.360 (0.034) 0.024 (0.003) 0.3456 (0.002) 0.544 (0.041) 0.2463 (0.006) 
 Myostatin 0.954 (0.002) 0.218 (0.008) 0.1496 (0.042) 0.1653 (0.001) 0.4496 (0.031) 
 Aggrecan 47.869 (0.792) 0.0449 (0.007) 42.593 (1.921) 12.414 (1.225) 24.620 (0.208) 
 TGF2 0.007 (7.023) 0.0117 (0.001) 0.4363 (0.022) 0.2623 (0.006) 0.0231 (0.002) 
 Collagen 1A 14.718 (2.411) 0.0040 (0.003) 25.213 (4.873) 14.354 (2.560) 23.793 (4.581) 
 Follistatin 5.570 (0.420) 1.4783 (0.017) 18.455 (0.113) 5.5201 (0.292) 6.849 (0.048) 
 Decorin 1.418 (0.400) 0.7386 (0.083) 2.6396 (0.250) 2.5736 (0.014) 1.4256 (0.375) 
 IGF1 3.740 (0.034) 0.1343 (0.003) 0.2313 (0.011) 0.3846 (0.001) 0.3246 (0.011) 
 Slow Troponin-I 0.151 (0.002) 0.0353 (0.002) 0.348 (0.000) 0.0533 (0.000) 0.3796 (0.010) 
 Fast Troponin-I 2.2678 (0.017) 0.4483 (0.004) 0.1966 (0.007) 2.2673 (0.025) 13.329 (1.235) 
 GAP43 2.993 (0.164) 0.0144 (0.002) 1.438 (0.023) 1.5366 (0.015) 2.67 (0.026) 
 HN1 0.4773 (0.206) 0.0916 (0.002) 0.449 (0.041) 0.274 (0.004) 0.325 (0.190) 
 Mhc3, embryonic 156.95 (6.412) 2.0276 (0.014) 76.603 (2.269) 63.824 (1.841) 77.206 (2.081) 
 Myogenin 12.482 (0.100) 2.6596 (0.024) 10.371 (0.365) 1.914 (0.064) 6.66 (0.027) 
 MEFf2A 2.9286 (0.003) 2.4173 (0.210) 1.5726 (0.021) 0.4437 (0.018) 1.3303 (0.029) 
 MyoD 1.656 (0.010) 1.5143 (0.268) 1.0403 (0.015) 0.5466 (0.015) 1.7436 (0.043) 
 Mhc7, slow 0.3546 (0.002) 1.5528 (0.021) 0.126 (0.004) 0.1166 (0.003) 0.246 (0.002) 
 Mhc4,fast 0.5615 (0.024) 1.2582 (0.033) 0.2517 (0.002) 0.35 (0.020) 0.8596 (0.018) 
 Sirt1 2.9526 (0.026) 1.5503 (0.032) 0.648 (0.027) 0.1588 (0.018) 3.2756 (0.068) 
 GDNF 18.504 (0.095) 0.0288 (0.000) 45.463 (0.101) 4.3611 (0.021) 14.996 (2.750) 
 Shh 5.1596 (0.008) 0.0067 (0.000) 4.6673 (0.276) 8.3193 (0.486) 5.6623 (0.147) 
 PGC-1A 2.4663 (0.311) 1.1812 (0.060) 1.2613 (0.018) 1.7346 (0.033) 5.3616 (0.289) 
 MuRF-1 3.2543 (0.018) 0.0014 (3.785) 1.1063 (0.002) 0.2643 (0.003) 2.174 (0.000) 
 Atrogin-1 2.5396 (0.030) 0.0016 (0.000) 1.641 (0.143) 0.518 (0.000) 1.4476 (0.039) 
 Complement-3 22.608 (0.161) 0.0307 (0.030) 11.392 (1.064) 2.9605 (0.017) 12.286 (0.170) 
 Calpain-3 0.225 (0.006) 1.3406 (0.103) 0.2783 (0.020) 1.944 (0.034) 0.2943 (0.003) 
 CNTF 0.5506 (0.037) 1.479 (0.008) 0.256 (0.003) 0.1133 (0.013) 1.8046 (0.002) 
 AMPK 1.972 (0.028) 0.4676 (0.006) 1.054 (0.017) 0.354 (0.004) 4.4383 (0.022) 
 NT4 0.246 (0.002) 1.14 (0.026) 0.7716 (0.013) 14.280 (0.311) 1.2553 (0.089) 
Desmin 0.408 (0.005) 0.077 (0.051) 0.282 (0.003) 0.190 (0.011) 0.104 (0.004) 
Vimentin 1.350 (0.063) 0.063 (0.002) 0.425 (0.004) 2.817 (0.129) 0.244 (0.003) 





Post Repair Week:  12 Weeks     
Group NegC PosC DN PN RN 
N 3 3 3 5 3 
 EGF 0.2283 (0.021) 1.2168 (0.014) 2.442 (0.309) 3.2406 (0.049) 0.4313 (0.011) 
 HGF 0.87 (0.021) 0.0349 (0.003) 0.557 (0.036) 0.741 (0.027) 1.7323 (0.123) 
 Galectin-1 0.1623 (0.039) 0.023 (0.002) 0.1653 (0.028) 0.1138 (0.002) 0.197 (0.002) 
 Myostatin 0.771 (0.015) 0.2365 (0.037) 0.8563 (0.021) 0.1056 (0.002) 0.566 (0.004) 
 Aggrecan 4.6276 (0.286) 0.0226 (0.015) 7.6986 (0.133) 0.2432 (0.038) 2.158 (0.033) 
 TGF2 0.0245 (0.001) 0.0119 (0.000) 0.219 (0.008) 0.0181 (0.004) 0.0225 (0.001) 
 Collagen 1A 6.221 (0.065) 0.0040 (0.002) 15.765 (0.160) 3.2546 (0.337) 0.136 (0.028) 
 Follistatin 2.5653 (0.211) 1.423 (0.013) 8.133 (0.028) 2.3658 (0.109) 1.3883 (0.105) 
 Decorin 1.4186 (0.029) 0.5655 (0.349) 2.5103 (0.417) 11.286 (0.257) 0.6413 (0.045) 
 IGF1 0.1683 (0.023) 0.1337 (0.003) 0.154 (0.003) 0.0158 (0.002) 0.109 (0.004) 
 Slow Troponin-I 0.3472 (0.024) 0.0348 (0.003) 4.479 (0.337) 0.0428 (0.001) 0.3763 (0.006) 
 Fast Troponin-I 0.6238 (0.023) 0.4197 (0.008) 0.143 (0.021) 0.4528 (0.028) 1.6343 (0.274) 
 GAP43 1.3516 (0.214) 0.0146 (0.002) 0.5973 (0.065) 0.8562 (0.026) 0.8226 (0.111) 
 HN1 0.371 (0.050) 0.096 (0.002) 0.2326 (0.002) 0.5368 (0.005) 0.528 (0.000) 
 Mhc3, embryonic 17.930 (2.731) 2.0512 (0.023) 29.44 (0.426) 12.832 (1.085) 3.376 (0.012) 
 Myogenin 9.503 (0.041) 2.6532 (0.022) 10.816 (0.166) 1.6616 (0.042) 3.5496 (0.033) 
 MEF2A 2.3806 (0.016) 2.3257 (0.253) 3.1533 (0.007) 0.7274 (0.014) 1.334 (0.041) 
 MyoD 1.952 (0.012) 1.639 (0.069) 4.4956 (0.299) 2.4596 (0.014) 2.4883 (0.568) 
 Mhc7, slow 0.112 (0.001) 1.5251 (0.013) 0.4563 (0.025) 0.2248 (0.003) 0.2294 (0.005) 
 Mhc4,fast 0.2634 (0.042) 1.276 (0.025) 0.0433 (0.003) 1.1356 (0.029) 1.1252 (0.021) 
 Sirt1 0.9266 (0.020) 1.5388 (0.010) 1.5629 (0.032) 3.4362 (0.270) 1.6446 (0.042) 
 GDNF 11.499 (0.241) 0.0235 (0.003) 17.783 (2.040) 2.2266 (0.023) 7.496 (0.431) 
 Shh 1.334 (0.150) 0.0051 (0.003) 2.0489 (0.028) 1.6432 (0.032) 6.6096 (0.364) 
 PGC-1A 0.119 (0.023) 1.1709 (0.050) 3.4966 (0.236) 0.2608 (0.021) 14.995 (2.615) 
 MuRF-1 1.552 (0.029) 0.0014 (3.872) 3.4423 (0.029) 0.3646 (0.003) 1.274 (0.019) 
 Atrogin-1 1.3713 (0.022) 0.0013 (0.000) 3.7636 (0.026) 0.325 (0.002) 0.8763 (0.061) 
 Complement-3 3.6280 (0.025) 0.0419 (0.030) 6.6664 (0.110) 1.8367 (0.012) 8.418 (0.726) 
 Calpain-3 0.5953 (0.003) 1.4335 (0.051) 0.1496 (0.025) 0.452 (0.035) 0.9473 (0.031) 
 CNTF 0.8364 (0.024) 1.4287 (0.035) 1.349 (0.021) 1.9340 (0.018) 0.4886 (0.004) 
 AMPK 1.5496 (0.004) 0.4427 (0.034) 0.4836 (0.003) 2.9613 (0.020) 1.3478 (0.019) 
 NT4 0.0657 (0.004) 1.1375 (0.018) 24.869 (3.530) 0.5672 (0.014) 13.682 (0.843) 
Desmin 0.216 (0.008) 0.131 (0.010) 0.128 (0.034) 0.131 (0.019) 0.205 (0.008) 
Vimentin 0.107 (0.002) 0.063 (0.003) 0.821 (1.073) 0.215 (0.004) 0.024 (0.006) 





Appendix 6. Homogenous Subset Tables for RQ data.   
ANOVA with post-hoc comparison using Scheffe’s for real-time PCR data (SPSS Inc.) 
MuRF1 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 9 
PosC2 3 .00                 
PosC12 4 .00                 
PN2 3   .26               
PN12 5     .36             
DN2 3       1.11           
RN12 3         1.27         
NegC12 3           1.55       
RN2 3             2.17     
NegC2 3               3.25   
DN12 3                 3.44 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Atrogin-1 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 
PosC12 4 .00               
PosC2 3 .00               
PN12 5   .33             
PN2 3     .52           
RN12 3       .88         
NegC12 3         1.37       
RN2 3         1.45       
DN2 3           1.64     
NegC2 3             2.54   
DN12 3               3.76 
Sig.   1.00 1.00 1.00 1.00 .91 1.00 1.00 1.00 
Myostatin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 
PN12 5 .11               
DN2 3 .15 .15             
PN2 3 .17 .17 .17           
PosC2 3   .22 .22           
PosC12 4     .24           
RN2 3       .45         
RN12 3         .57       
NegC12 3           .77     
DN12 3             .86   
NegC2 3               .95 




 n Subset for alpha = 0.05 
1 2 3 4 
NegC2 3 .0071       
PosC2 3 .0118       
PosC12 4 .0120       
PN12 5 .0182       
RN12 3 .0226       
RN2 3 .0230       
NegC12 3 .0245       
DN12 3   .2190     
PN2 3     .2623   
DN2 3       .4363 
Sig.   .530 1.000 1.000 1.000 
 
Decorin 
 n Subset for alpha = 0.05 
1 2 3 
PosC12 4 .57     
RN12 3 .64     
PosC2 3 .74     
NegC2 3 1.42     
NegC12 3 1.42     
RN2 3 1.43     
DN12 3   2.51   
PN2 3   2.57   
DN2 3   2.64   
PN12 5     11.29 
Sig.   .13 1.00 1.00 
 
Follistatin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
RN12 3 1.39 
          
PosC12 4 1.42 
          
PosC2 3 1.48 








        
PN2 3 
    
5.52 
      
NegC2 3 
    
5.57 
      
RN2 3 
      
6.85 
    
DN12 3 




          
18.46 









 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
PosC12 4 .0227             
PosC2 3 .0449             
PN12 5 .2432             
RN12 3 2.1580 2.1580           
NegC12 3   4.6277           
DN12 3     7.6987         
PN2 3       12.4143       
RN2 3         24.6207     
DN2 3           42.5930   
NegC2 3             47.8697 
Sig.   .185 .074 1.000 1.000 1.000 1.000 1.000 
 
Galectin-1 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
PosC12 4 0.02 
          
PosC2 3 0.02 












      
RN12 3 
    
0.20 0.20 
    
RN2 3 
      
0.25 
    
DN2 3 








          
0.54 
Sig.   1.00 0.45 0.89 0.51 1.00 1.00 
 
CNTF 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 
PN2 3 0.11 




            
RN12 3 
    
0.49 
          
NegC2 3 
    
0.55 
          
NegC12 3 
      
0.84 
        
DN12 3 
        
1.35 
      
PosC12 4 
          
1.43 
    
PosC2 3 
          
1.48 
    
RN2 3 




              
1.93 




 n Subset for alpha = 0.05 
1 2 3 4 
NegC12 3 0.23       
RN2 3 0.28       
RN12 3 0.43       
DN2 3 0.52       
NegC2 3 0.56       
PN2 3   1.14     
PosC12 4   1.22     
PosC2 3   1.25     
DN12 3     2.44   
PN12 5       3.24 
Sig.   0.07 0.99 1.00 1.00 
 
HGF 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 
PosC2 3 0.03 
              
PosC12 4 0.04 








          
NegC12 3 
    
0.87 
          
RN2 3 
      
1.24 
        
RN12 3 
        
1.73 
      
DN2 3 
          
2.34 
    
NegC2 3 




              
7.55 
Sig.   1.00 0.06 0.41 1.00 1.00 1.00 1.00 1.00 
 
GDNF 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
PosC12 4 0.02           
PosC2 3 0.03           
PN12 5 2.23 2.23         
PN2 3   4.36 4.36       
RN12 3     7.50       
NegC12 3       11.50     
RN2 3       15.00 15.00   
DN12 3         17.78   
NegC2 3         18.50   
DN2 3           45.46 








 n Subset for alpha = 0.05 
1 2 3 4 5 
DN12 3 0.15         
NegC2 3 0.23         
DN2 3 0.28         
RN2 3 0.29         
PN12 5   0.45       
NegC12 3   0.60       
RN12 3     0.95     
PosC2 3       1.34   
PosC12 4       1.43   
PN2 3         1.94 
Sig.   0.07 0.08 1.00 0.57 1.00 
 
PGC-1 
 n Subset for alpha = 0.05 
1 2 3 4 
NegC12 3 0.12       
PN12 5 0.26       
PosC12 4 1.18 1.18     
PosC2 3 1.18 1.18     
DN2 3 1.26 1.26     
PN2 3 1.73 1.73     
NegC2 3 2.47 2.47     
DN12 3   3.50 3.50   
RN2 3     5.36   
RN12 3       15.00 
Sig.   0.18 0.19 0.47 1.00 
 
NT4 
 n Subset for alpha = 0.05 
1 2 3 
NegC12 3 0.07     
NegC2 3 0.25     
PN12 5 0.57     
DN2 3 0.77     
PosC12 4 1.14     
PosC2 3 1.14     
RN2 3 1.26     
RN12 3   13.68   
PN2 3   14.28   
DN12 3     24.87 






 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
PN12 5 0.02 
















        
NegC12 3 
    
0.17 
        
DN2 3 
      
0.23 
      
RN2 3 
        
0.33 
    
PN2 3 




            
3.74 
Sig.   1.00 0.09 0.35 1.00 1.00 1.00 1.00 
 
Complement-3 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
PosC2 3 0.03 
            
PosC12 4 0.04 








        
NegC12 3 
    
3.63 
        
DN12 3 
      
6.67 
      
RN12 3 
        
8.42 
    
DN2 3 








            
22.61 
Sig.   1.00 0.21 0.84 1.00 1.00 0.51 1.00 
 
Myosin Heavy Chain-Embryonic 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
PosC2 3 2.03           
PosC12 4 2.05           
RN12 3 3.38           
PN12 5   12.83         
NegC12 3   17.93         
DN12 3     29.44       
PN2 3       63.82     
DN2 3         76.60   
RN2 3         77.21   
NegC2 3           156.96 




Myosin Heavy Chain-Slow 
 n Subset for alpha = 0.05 
1 2 3 4 5 
NegC12 3 0.11         
PN2 3 0.12         
DN2 3 0.13         
PN12 5   0.23       
RN12 3   0.23       
RN2 3   0.25       
NegC2 3     0.36     
DN12 3       0.46   
PosC12 4         1.53 
PosC2 3         1.55 
Sig.   0.98 0.78 1.00 1.00 0.45 
 
Myosin Heavy Chain-Fast 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
DN12 3 0.04 








        
PN2 3 
    
0.35 
        
NegC2 3 
      
0.56 
      
RN2 3 
        
0.86 
    
RN12 3 








            
1.26 
PosC12 4 
            
1.28 
Sig.   1.00 1.00 0.08 1.00 1.00 1.00 1.00 
 
AMPK-1 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 
PN2 3 0.35 












            
DN2 3 
    
1.05 
          
RN12 3 
      
1.35 
        
NegC12 3 
        
1.55 
      
NegC2 3 
          
1.97 
    
PN12 5 




              
4.44 




 n Subset for alpha = 0.05 
1 2 3 4 5 
PN2 3 0.16         
DN2 3   0.65       
NegC12 3   0.93       
PosC12 4     1.54     
PosC2 3     1.55     
DN12 3     1.56     
RN12 3     1.65     
NegC2 3       2.95   
RN2 3       3.28 3.28 
PN12 5         3.44 




 n Subset for alpha = 0.05 
1 2 
PosC12 4 0.04   
PosC2 3 0.04   
PN12 5 0.04   
PN2 3 0.05   
NegC2 3 0.15   
NegC12 3 0.35   
DN2 3 0.35   
RN12 3 0.38   
RN2 3 0.38   
DN12 3   4.48 




 n Subset for alpha = 0.05 
1 2 3 4 
DN12 3 0.14       
DN2 3 0.20       
PosC12 4 0.42 0.42     
PosC2 3 0.45 0.45     
PN12 5 0.45 0.45     
NegC12 3 0.62 0.62     
RN12 3   1.63 1.63   
PN2 3     2.27   
NegC2 3     2.27   
RN2 3       13.33 









 n Subset for alpha = 0.05 
1 2 3 4 5 6 
PosC12 4 0.01           
PosC2 3 0.01           
NegC12 3   1.33         
PN12 5   1.64         
DN12 3   2.05         
DN2 3     4.67       
NegC2 3     5.16 5.16     
RN2 3       5.66     
RN12 3         6.61   
PN2 3           8.32 
Sig.   1.00 0.07 0.46 0.43 1.00 1.00 
 
MyoD 
 n Subset for alpha = 0.05 
1 2 3 4 5 
PN2 3 0.55 
        
DN2 3 1.04 1.04 












    
RN2 3 
  
1.74 1.74 1.74 
  
NegC12 3 












        
4.50 
Sig.   0.46 0.08 0.63 0.05 1.00 
 
Myogenin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
PN12 5 1.66             
PN2 3 1.91             
PosC12 4   2.65           
Posc2 3   2.66           
RN12 3     3.55         
RN2 3       6.66       
NegC12 3         9.50     
DN2 3           10.37   
DN12 3           10.82   
NegC2 3             12.48 





 n Subset for alpha = 0.05 
1 2 3 4 
PN2 3 0.44       
PN12 5 0.73       
RN2 3   1.33     
RN12 3   1.33     
DN2 3   1.57     
PosC12 4     2.33   
NegC12 3     2.38   
PosC2 3     2.42   
NegC2 3       2.93 
DN12 3       3.15 
Sig.   0.38 0.60 1.00 0.69 
 
Nestin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 8 
PosC2 3 0.04 
              
PosC12 4 0.04 




            
RN12 3 
    
0.10 
          
NegC12 3 
    
0.10 
          
PN2 3 
      
0.13 
        
DN12 3 
        
0.20 
      
NegC2 3 
          
0.40 
    
DN2 3 




              
0.57 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
Vimentin 
 n Subset for alpha = 0.05 
1 2 
RN12 3 0.02   
PosC12 4 0.06   
PosC2 3 0.06   
NegC12 3 0.11   
NegC2 3 0.14   
PN12 5 0.22   
RN2 3 0.24   
DN2 3 0.43   
DN12 3 0.82   
PN2 3   2.82 




 n Subset for alpha = 0.05 
1 2 3 4 
PosC2 3 0.10 
      
RN2 3 0.10 
      
DN12 3 0.13 
      
PosC12 4 0.13 
      
PN12 5 0.13 












    
DN2 3 




      
0.41 
Sig.   0.67 0.78 1.00 1.00 
 
Collagen-1 
 n Subset for alpha = 0.05 
1 2 3 4 
PosC2 3 0.00 
      
PosC12 4 0.00 
      
RN12 3 0.14 
      
PN12 5 3.26 
      
NegC12 3 6.22 














    
23.79 23.79 
DN2 3 
      
25.21 
Sig.   0.25 1.00 0.05 1.00 
 
HN-1 
 n Subset for alpha = 0.05 
1 2 
PosC2 3 0.09   
PosC12 4 0.10   
DN12 3 0.23 0.23 
PN2 3 0.27 0.27 
RN2 3 0.33 0.33 
NegC12 3 0.37 0.37 
DN2 3   0.45 
NegC2 3   0.48 
RN12 3   0.53 
PN12 5   0.54 






 n Subset for alpha = 0.05 
1 2 3 4 
PosC2 3 0.01 
      
PosC12 4 0.02 












    
NegC12 3 












      
2.67 
NegC2 3 
      
2.99 




 n Subset for alpha = 0.05 
1 2 
RN12 3 23.30   
NegC 3 23.41 23.41 
PN2 3 23.46 23.46 
DN2 3 23.51 23.51 
PosC12 3 23.91 23.91 
NegC12 3 24.08 24.08 
DN12 3 24.12 24.12 
RN2 3 24.28 24.28 
PosC2 3 24.35 24.35 
PN12 3   24.49 





















Appendix 7. Homogenous Subset Tables for Optical densitometry data 
 
R-Spondin-1 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .01             
DN12 3   .47           
PN12 3     .50         
RN12 3       .59       
RN2 3         .68     
DN2 3           .92   
PN2 3             1.00 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
Vimentin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
DN12 3 .25           
RN12 3   .28         
PN12 3   .29         
RN2 3     .34       
Csham2 3       .57     
DN2 3         .75   
PN2 3           .88 
Sig.   1.00 .09 1.00 1.00 1.00 1.00 
 
Desmin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
DN12 3 .6067           
DN2 3   .7800         
RN2 3     .8233       
PN12 3       .9800     
RN12 3         1.0867   
PosC2 3         1.0967   
PN2 3           1.3933 










 n Subset for alpha = 0.05 
1 2 3 4 5 
Csham2 3 .71         
RN12 3   1.33       
PN2 3   1.33       
DN12 3     1.39     
DN2 3       1.46   
RN2 3       1.47   
PN12 3         1.57 





 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .50             
DN12 3   .64           
PN12 3     .70         
RN12 3       .84       
RN2 3         1.71     
DN2 3           1.95   
PN2 3             2.38 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
TGF2 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .34             
PN12 3   .42           
RN12 3     .57         
DN12 3       .65       
RN2 3         .71     
PN2 3           .78   
DN2 3             .85 











 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .87             
PN12 3   1.24           
RN2 3     1.26         
DN2 3       1.54       
DN12 3         1.62     
RN12 3           1.80   
PN2 3             1.96 





 n Subset for alpha = 0.05 
1 2 3 4 5 6 
DN12 3 .31           
RN2 3   .77         
DN2 3     .80       
PN2 3       .82     
PN12 3       .83     
RN12 3         .87   
Csham2 3           1.04 




 n Subset for alpha = 0.05 
1 2 3 4 
PN2 3 .01       
Csham2 3 .01       
DN2 3 .01       
RN2 3 .01       
RN12 3   .11     
PN12 3     .16   
DN12 3       .17 









phospho-p38 vs -Tubulin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .24             
PN12 3   .98           
DN2 3     1.21         
RN12 3       1.33       
RN2 3         1.42     
DN12 3           1.63   
PN2 3             1.82 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
phospho-Erk1 vs -Tubulin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .04             
RN12 3   .24           
RN2 3     .51         
DN12 3       .54       
PN2 3         .65     
PN12 3           .69   
DN2 3             .86 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
phospho-Erk2 vs -Tubulin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .04             
RN12 3   .32           
DN12 3     .56         
RN2 3       .68       
PN2 3         .84     
PN12 3           .89   
DN2 3             .96 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
 
phospho-SMAD2 vs Tubulin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
Csham2 3 .04           
RN2 3   .50         
RN12 3   .51         
XXIII 
 
PN2 3     .61       
PN12 3       .63     
DN2 3         .84   
DN12 3           .86 
Sig.   1.00 .06 1.00 1.00 1.00 1.00 
 
 
phospho-SMAD3 vs -Tubulin 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .04             
RN2 3   .36           
DN2 3     .41         
RN12 3       .42       
PN12 3         .43     
DN12 3           .52   
PN2 3             .64 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
 
phospho-p38 vs Total p38 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
Csham2 3 .23           
PN12 3   .55         
RN12 3     .56       
DN12 3       .60     
DN2 3         .61   
PN2 3         .61   
RN2 3           .63 
Sig.   1.00 1.00 1.00 1.00 .74 1.00 
 
 
phospho-Erk1 vs Total Erk 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
Csham2 3 .03           
RN12 3   .15         
DN12 3     .45       
PN2 3       .49     
RN2 3         .65   
DN2 3           .72 
PN12 3           .72 
XXIV 
 
Sig.   1.00 1.00 1.00 1.00 1.00 .74 
 
 
phospho-Erk2 vs Total Erk 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .03             
RN12 3   .20           
DN12 3     .47         
PN2 3       .63       
DN2 3         .80     
RN2 3           .86   
PN12 3             .94 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
phospho-SMAD2 vs Total SMAD 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
Csham2 3 .07             
RN12 3   .50           
RN2 3     .56         
PN2 3       .84       
DN12 3         .98     
PN12 3           1.21   
DN2 3             1.26 
Sig.   1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
 
phospho-SMAD3 vs Total SMAD 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 
Csham2 3 .08           
RN2 3   .40         
RN12 3   .41         
DN12 3     .59       
DN2 3       .62     
PN12 3         .83   
PN2 3           .87 
Sig.   1.00 .31 1.00 1.00 1.00 1.00 
 
Myosin Heavy Chain-Slow 
 n Subset for alpha = 0.05 
1 2 3 4 5 
XXV 
 
PN12 3 .62         
DN12 3   .63       
RN2 3     .66     
Csham2 3     .67     
RN12 3       .78   
PN2 3         .80 
DN2 3         .80 
Sig.   1.00 1.00 .09 1.00 1.00 
 
Myosin Heavy Chain-Fast (2b) 
 n Subset for alpha = 0.05 
1 2 3 4 5 6 7 
DN12 3 .14             
RN12 3   .19           
DN2 3     .26         
PN12 3       .36       
PN2 3         .38     
RN2 3           .49   
Csham2 3             .58 




 n Subset for alpha = 0.05 
1 2 3 4 
PosC2 3 0.00       
NegC2 3 0.00       
NegC12 3 0.00       
PN12 3   2920.33     
DN12 3   2927.00 2927.00   
RN2 3   2940.00 2940.00 2940.00 
PosC12 3     2965.00 2965.00 
PN2 3     2965.00 2965.00 














Appendix 8. Overall Relative Fold Change of the Gene Expression for All Markers 
 Gene PN DN  RN  NegC  






 -73.84 -139.02* 
2 Fast myosin HC 0.79 -0.21
#
 0.27* -0.29* 
3 Slow myosin HC 0.11 0.33
#
 -0.02 -0.24* 
4 Fast troponin-I -1.81 -0.054 -11.69* -1.64 
5 Slow troponin-I -0.01 4.13
#




















9 TGFb2 -0.24* -0.22
*,#










 -0.13 -0.78 0.01 
12 Follistatin -3.15 -10.32
*,#
 -5.46* -3.00 







 0.15 -0.33 
15 IGF-1 -0.37
*#
 -0.08* -0.22* -3.58* 
16 NT-4 -13.71 24.10
#
 12.43 -0.18 








19 Sonic Hedgehog -6.68* -2.62 0.95
#
 -3.83 
20 Calpain-3 -1.49* -0.13 0.65
#
 0.37 
21 PGC-1a -1.48 2.24 9.64
#
 -2.35 
22 Sirt-1 3.28* 0.92 -1.63 -2.03 
23 Galectin-1 -0.43* -0.18 -0.05 -0.20 

















27 myoD 1.91 3.46
#
 0.75 0.30 
28 Mef-2a 0.28 1.58 0.01 -0.55 
29 Desmin 0.02 -0.15
*
 0.10 -0.19* 










32 GAP-43 -0.68 -0.84 -1.85 -1.64 
33 HN-1 0.26 -0.21 0.20 -0.11 


















Appendix 9. Summary of techniques used to detect expression level of each marker 






1 Neurotrophic factor-4, NT-4 √   
2 Glial derived neurotrophic factor,   GDNF √   
3 Ciliary neurotrophic factor CNTF  √   
4 Insulin-like growth factor, IGF1 √   
5 Hepatocyte Growth Factor, HGF √   
6 Epidermal Growth Factor,EGF √   
7 Sonic hedgehog, Shh √   
8 MyoD √ √  
9 Myogenin √ √  
10 MEF2A √   
11 Desmin √ √ √ 
12 Vimentin √ √ √ 
13 Nestin √  √ 
14 Atrogin-1 √   
15 MuRF-1 √   
16 Peroxisome proliferator activated receptor-gamma 
co-activator, alpha, PGC-1 
√   
17 Sirt-1 √   
18 Myostatin √   
19 Calpain-3 √   
20 Complement 3 √   
21 AMP-activated protein kinase alpha 1 subunit, 
AMPK-1a 
√   
22 Follistatin √   
23 Transforming Growth Factor beta 2, TGF2 √ √  
24 Collagen Type 1 alpha, Col-1a √   
25 aggrecan (chondroitin sulphate proteoglycan-1) √   
26 Galectin-1 √ √ √ 
27 Decorin √   
28 Fast skeletal troponin-I √   
29 Embryonic myosin heavy chain 3 √   
30 Fast skeletal myosin heavy chain 4 √ √  
31 Slow skeletal myosin heavy chain 7 √ √  
32 Slow skeletal troponin-I √   
33 Lamin A √   
34 Hematological and neurological expressed-1, HN1 √   
35 Growth associated protein 43, GAP43 √   
36 alpha-tubulin  √  
37 Connective tissue growth factor  √  
38 alpha-smooth muscle actin, a-SMA  √  
39 Erk1 and 2 and phospho-Erk 1 and 2  √  
40 SMAD 2 and 3 and phospho-SMAD2 and 3  √  
41 p38 and phospho-p38  √  
42 R-spondin-1  √ √ 
Note: Gene expression assays for R-spondin-1, a-SMA and CTGF were not done because the 




Appendix 10.   Optical Densitometry values for Western Blot Data 
 
OD values are shown in means ± standard deviation, n=3 per treatment group. NegC is not 
included in the analysis because the samples were exhausted in previous projects. 
 
2 weeks 
    
Group PosC DN-2 PN-2 RN-2 
Sample size 3 3 3 3 
R-spondin-1 
0.0053(0.0008
8) 0.91(0.0018) 0.99 (0.012) 0.67(0.00075) 
CTGF 0.86(0.0021) 1.53(0.0026) 1.96(0.0014) 1.25(0.0014) 
a-SMA 0.70 (0.0033) 1.46 (0.0012) 
1.33 
(0.00204) 1.46 (0.0016) 
Galectin-1 0.50 (0.0030) 1.95 (0.0010) 2.37 (0.0026) 1.70 (0.0020) 
TGFb2 
0.34 
(0.00067) 0.85 (0.0015) 0.77 (0.0024) 0.71 (0.0018) 
Desmin 
1.09 
(0.00084) 0.77 (0.0017) 1.39 (0.0024) 0.82 (0.0026) 
Vimentin 
0.568 












(0.00088) 0.79 (0.012) 
0.82 
(0.00081) 0.77 (0.0015) 
fast myosin heavy 
chain-2B 0.58 (0.0018) 0.26 (0.0016) 0.37 (0.0020) 0.48 (0.0011) 
slow myosin heavy 
chain 0.66 (0.0022) 
0.80 
(0.002015508) 0.79 (0.0026) 0.66 (0.0020) 
 
12 weeks 
    
Group PosC DN-12 PN-12 RN-12 
Sample size 3 3 3 3 
R-spondin-1 0 0.46 (0.0032) 0.29 (0.28) 0.58 (0.0029) 
CTGF 0 1.62 (0.0013) 0.74 (0.71) 1.79 (0.0027) 
a-SMA 0 1.39 (0.0021) 0.94 (0.90) 1.32 (0.0027) 
Galectin-1 0 0.64 (0.0025) 0.41 (0.40) 0.83 (0.0015) 
TGFb2 0 0.65 (0.0012) 0.24 (0.23) 0.56 (0.0023) 
Desmin 0 0.60 (0.0022) 0.58 (0.56) 1.08 (0.0029) 
Vimentin 0 0.25 (0.0016) 0.17 (0.16) 0.27 (0.00077) 
myoD 0 0.17 (0.00079) 0.092 (0.087) 0.11 (0.0016) 
myogenin 0 0.30 (0.00091) 0.49 (0.48) 0.86 (0.0011) 
fast myosin heavy chain-2B 0 0.14 (0.0012) 0.211 (0.206) 0.18 (0.0016) 




Appendix 11.  Overall Relative Fold Change of the Protein Expression for Selected 
Markers 
  
Protein PN  p-value DN  p-value RN  p-value 
R-spondin-1 0.298 *# 0.509 *# 0.866 *# 
CTGF 0.379 *# 1.057 *# 1.430 *# 
a-SMA 0.710 # 0.952 # 0.905 nil 
Galectin-1 0.176 *# 0.328 *# 0.4918 *# 
TGFb2 0.320 *# 0.768 *# 0.7991 *# 
Desmin 0.423 *# 0.779 *# 1.3157 * 
Vimentin 0.195 * 0.339 *# 0.803 * 
myoD 15.603 # 23.794 # 16.445 # 
myogenin 0.606 nil 0.386 *# 1.118 *# 
slow myosin heavy chain 0.467 # 0.784 # 1.178 # 
fast myosin heavy chain-2B 0.568 *# 0.544 *# 0.379 *# 
 
Note:  
* p<0.05 at 2-weeks 



























Appendix 12.  Pearson Correlation Analysis for Selected Markers  
RQ and OD triplicates were in the Pearson correlation analysis. Selected markers from each 
category were set as the dependent and independent variables. Pearson correlation 
coefficients (r) and the significance levels are reported as follows: 
1 = 0.01<p<0.05 
2 = 0.001<p<0.01 
3 = p<0.001  
 
Dependent Variable Independent Variable r Significance Level 
 Collagen-1a CTGF 0.3566 1 
  HGF 0.3903 1 
  Vimentin 0.4051 1 
  a-SMA 0.421 1 
  Sonic Hedgehog 0.5246 2 
  R-spondin-1 0.5935 3 
  TGFb2 0.6407 3 
  Galectin-1 0.6537 3 
  GDNF 0.7735 3 
 
Aggrecan 0.7748 3 
 
 
Dependent Variable Independent Variable r Significance Level 
aggrecan CNTF -0.4783 2 
  EGF -0.4568 2 
  HGF 0.3991 1 
  TGFb2 0.43 1 
  Sonic Hedgehog 0.4969 2 
  Galectin-1 0.6324 3 
  IGF-1 0.6986 3 
 
Collagen-1a 0.7748 3 
  GDNF 0.7856 3 
 
 
Dependent Variable Independent Variable r Significance Level 
vimentin Sirt-1 -0.4739 2 
 
CNTF -0.4332 1 
 
CTGF 0.5017 2 
  NT-4 0.5147 2 
  TGFb2 0.5159 2 
  Sonic Hedgehog 0.5335 2 
  Galectin-1 0.5467 3 
  HGF 0.5671 3 
 





Dependent Variable Independent Variable r Significance Level 
Decorin Myostatin -0.4234 1 
 
AMPK-1a 0.4420 1 
 
CNTF 0.4719 2 
 
HN1 0.4849 2 
 
Sirt1 0.5334 2 
 
EGF 0.8214 3 
 
Dependent Variable Independent Variable r Significance Level 
Follistatin GAP43 0.3563 1 
 
Desmin 0.3709 1 
 
Embryonic myosin heavy chain 0.5010 2 
 
Myogenin 0.5833 3 
 
 
Dependent Variable Independent Variable r Significance Level 
Atrogin-1 Fast myosin HC -0.7585 3 
  Calpain-3 -0.6758 3 
  Slow myosin HC -0.4102 1 
  Myostatin 0.7753 3 
  Myogenin 0.8659 3 
 
MuRF1 0.9471 3 
 
 
Dependent Variable Independent Variable r Significance Level 
MuRF1 Calpain-3 -0.7066 3 
  Fast myosin HC -0.6068 3 
  Slow myosin HC -0.4108 1 
  Myogenin 0.8476 3 
  Myostatin 0.8712 3 
 












Dependent Variable Independent Variable r Significance Level 
myoD CTGF -0.4227 1 
 
TGFb2 -0.3873 1 
 
AMPK-1a -0.3653 1 
 
Mef-2a 0.3788 1 
 
IGF1 0.3864 1 
  CNTF 0.4168 1 
 
Myostatin 0.4611 2 
  EGF 0.4899 2 




Dependent Variable Independent Variable r Significance Level 
myogenin Fast myosin HC -0.7349 3 
  Myostatin -0.4499 2 
  EGF -0.3928 1 
  CNTF -0.3479 1 
  Slow troponin-I 0.4508 2 
  IGF-1 0.5418 2 
  Follistatin 0.5833 3 
  Mef-2a 0.633 3 
  Desmin 0.6338 3 
  GDNF 0.7514 3 
  Slow MHC 0.9229 3 
 
 
Dependent Variable Independent Variable r Significance Level 
GAP43 Follistatin 0.3563 1 
  HN-1 0.4349 1 
  GDNF 0.4441 2 
  HGF 0.4788 2 
  Sonic Hedgehog 0.6429 3 
  IGF-1 0.6643 3 














Dependent Variable Independent Variable r Significance Level 
Embryonic myosin heavy chain CNTF -0.4195 1 
 
myostatin 0.3958 1 
 
Follistatin 0.501 2 
 
HGF 0.535 2 
 
GDNF 0.5478 3 
 
Sonic Hedgehog 0.5566 3 
  Myogenin 0.6373 3 




Dependent Variable Independent Variable r Significance Level 
Fast myosin heavy chain Atrogin-1 -0.7585 3 
  Myogenin -0.7349 3 
 
TGFb2 -0.6738 3 
  MuRF-1 -0.6068 3 
  Myostatin -0.4796 2 
  NT-4 -0.4297 1 
  Mef-2a -0.3777 1 
  Complement-3 -0.3773 1 
  Sonic Hedgehog -0.3502 1 
 
CNTF 0.5359 2 
 
 
Dependent Variable Independent Variable r Significance Level 
Slow myosin heavy chain TGFb2 -0.3466 2 
 
Complement-3 -0.438 1 
  MuRF-1 -0.4108 1 
  Atrogin-1 -0.4102 1 
  IGF-1 -0.3741 1 
 
CNTF 0.3479 1 
  PGC-1a 0.3872 1 
  Mef-2a 0.4309 1 
  NT-4 0.4504 2 
  Sonic Hedgehog 0.4912 2 








Dependent Variable Independent Variable r Significance Level 
Fast troponin-I Sirt-1 -0.388 1 
  Sonic Hedgehog -0.4169 1 
 
 
Dependent Variable Independent Variable r Significance Level 
Slow troponin-I Myogenin 0.4508 2 
  Mef-2a 0.4847 2 
  Myostatin 0.4988 2 
  NT-4 0.7736 3 
 
 
Dependent Variable Independent Variable r Significance Level 
AMPK-1a CNTF 0.4909 2 
  Sirt1 0.7985 3 
 
 
Dependent Variable Independent Variable r Significance Level 
CNTF TGFb2 -0.5564 3 
 
AMPK-1a 0.4909 2 
 
EGF 0.5861 3 
 
Sirt1 0.7013 3 
 
 
Appendix 13.  Loss of Muscle Mass over 12-weeks  
 
Muscle mass is shown in means ± standard deviation, n=3 per treatment group. 
  
Group Mean muscle mass (g) Difference Loss of muscle mass (%)  
PN-2 0.544 (0.041) -0.219 21.90 
PN-12 0.325 (0.002)     
DN-2 1.054 (0.017) -0.5704 57.04 
DN-12 0.4836 (0.003)     
RN-2 0.481 (0.005) -0.278 27.80 
RN-12 0.203 (0.001)     
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